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ABSTRACT
Introduction Young women who sell sex (YWSS) in 
Zimbabwe remain at high risk of HIV infection. Effective HIV 
prevention strategies are needed. Through support to access 
a combination of evidence- based interventions, including oral 
pre- exposure prophylaxis (PrEP), the Determined, Resilient, 
Empowered, AIDS- free, Mentored and Safe (DREAMS) 
partnership aimed to reduce new HIV infections among 
adolescent girls and young women by 40% over 24 months.
Methods Non- randomised ‘plausibility’ evaluation, 
powered to detect a 40% HIV incidence difference between 
DREAMS and non- DREAMS sites. Two large cities with 
DREAMS funding were included, and four smaller non- 
DREAMS towns for comparison. In all sites, YWSS were 
enrolled to a cohort through peer- referral. Women were 
followed up for 24 months. HIV seroconversion was the 
primary outcome, with secondary outcomes identified 
through a theory of change. Outcomes were compared 
between YWSS recruited in DREAMS cities and non- 
DREAMS towns, adjusting for individual- level confounders 
and HIV prevalence at enrolment.
Results From April to July 2017, 2431 women were enrolled, 
1859 of whom were HIV negative at enrolment; 1019 of these 
women (54.8%) were followed up from March to May 2019 
and included in endline analysis. Access to clinical services 
increased, but access to socioeconomic interventions promoted 
by DREAMS was limited. A total of 79 YWSS HIV seroconverted, 
with HIV incidence among YWSS in DREAMS cities lower 
(3.1/100 person- years) than in non- DREAMS towns (5.3/100 
person- years). In prespecified adjusted analysis, HIV incidence 
was lower in DREAMS cities but with weak statistical evidence 
(adjusted rate ratio (RR)=0.68; 95% CI 0.40 to 1.19; p=0.18). 
Women in DREAMS cities were more likely to report ever 
and ongoing PrEP use, consistent condom use, fewer sexual 
partners and less intimate partner violence.
Conclusion It is plausible that DREAMS lowered HIV 
incidence among YWSS in two Zimbabwean cities, but our 
evaluation provides weak statistical evidence for impact 
and suggests any reduction in incidence was lower than 
the anticipated 40% decline. We identified changes to 
some important ‘pathways to impact’ variables, including 
condom use.
INTRODUCTION
In Eastern and Southern Africa, adolescent 
girls and young women (AGYW) aged 15–24 
accounted for 26% of all new HIV infections 
in 2018.1 Young women who sell sex (YWSS), 
including young female sex workers (FSW) 
and women who sell sex but do not identify 
as FSW, are at especially high risk because 
of their high numbers of sexual partners, 
constrained ability to negotiate condom use 
and high prevalence of other sexually trans-
mitted infections.2 3 Poverty, poor access 
to healthcare, stigma and discrimination, 
and physical and sexual violence further 
compound this risk.2 4 Reducing HIV infec-
tions among YWSS requires interventions 
that address these multiple determinants of 
risk.
In 2015, the DREAMS (Determined, Resil-
ient, Empowered, AIDS- free, Mentored 
and Safe) partnership was launched in ten 
sub- Saharan African countries, including 
Zimbabwe. Through financial and technical 
support for a combination of evidence- based 
interventions, DREAMS aimed to reduce 
new HIV infections among AGYW by 40% 
over 24 months.5 6 In Zimbabwe, interven-
tions included HIV testing, contraception 
and condom provision as well as the offer of 
oral pre- exposure prophylaxis (PrEP), with 
linkage to the broader package of DREAMS 
services.
We evaluated whether offering HIV testing 
services and increasing the availability of 
PrEP to YWSS aged 18–24, combined with 
community mobilisation and social protec-
tion interventions supported by DREAMS, 
reduced the number of new HIV infections 
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incidence among YWSS residing in areas where DREAMS 
investments were not available.
METHODS
Study design and participants
We conducted a non- randomised ‘plausibility’ evalua-
tion of the impact of DREAMS on HIV incidence and 
other secondary outcomes.7 Our ‘plausibility’ evaluation 
reflects that financial and practical issues limited the 
study size alongside other limitations such as the lack of 
randomisation.5 7 Our prespecified approach was to build 
the strength of the evidence base related to an impact of 
DREAMS on HIV incidence through combined analysis 
of outcome and qualitative process data.
The study was conducted with YWSS in two large 
cities and four smaller towns in Zimbabwe. The cities 
were selected purposively as locations where DREAMS 
funding was being provided. The four smaller towns were 
selected for comparison based on their similarity with the 
DREAMS cities according to data from the ‘Sisters with a 
Voice’ (Sisters) programme,5 a national HIV programme 
for sex workers. Sisters provides free, comprehensive HIV 
prevention and care services to FSW through a network 
of peer educators and clinics in line with WHO guidance, 
including: provision of free condoms and contraceptives, 
HIV testing, syndromic management of sexually trans-
mitted infections (STIs), community empowerment and 
legal advice supported by outreach workers and peer 
educators. In the DREAMS cities and one non- DREAMS 
town, Sisters was delivered through static sites open 5 days 
a week; in three of the four non- DREAMS towns, Sisters 
was delivered through mobile clinics in which service 
provision was only available 1 day per week.
The DREAMS interventions
In DREAMS cities, in addition to Sisters, a package of 
social and clinical interventions was available to YWSS. 
The DREAMS package was delivered through several 
implementing partners in the two cities; services available 
included social protection, life skills, education and voca-
tional training, gender- based violence prevention and 
care, and HIV prevention, including condom promo-
tion and distribution, an offer of PrEP combined with 
community empowerment and adherence support for 
those at highest risk of HIV (figure 1). Community- based 
activities aimed to increase demand for and uptake of 
PrEP and the DREAMS package more generally, and to 
support PrEP adherence. Entry into DREAMS could be 
through any implementing partner. In the non- DREAMS 
comparison towns YWSS could access usual care from the 
Sisters programme and the public health sector.
Cohort recruitment and follow-up
Within each city/town we recruited individuals into 
the study cohort through peer- referral using the same 
approach to respondent- driven sampling (RDS) we have 
used in previous surveys.2 5 YWSS were eligible to partic-
ipate if they were aged 18–24, had exchanged sex for 
money and/or material support in the past month, with 
it explicitly stated that sex acts with men would not have 
happened in the absence of an exchange, and if they 
were not planning to move from the site within the next 
6 months.
We conducted community mapping to identify hotspots 
where young women sell sex to select ‘seed’ participants.8 
Six seed participants were selected in each non- DREAMS 
town and 10 in each DREAMS city. Seed participants were 
given two coupons to recruit their peers. This process 
continued until the desired sample size was attained 
across both study groups. We previously described the 
participants enrolled at baseline, including details of 
the peer referral process.2 A summary of these and some 
additional analyses are reported in online supplemental 
appendix 5.
In both groups, YWSS were interviewed and offered 
HIV testing using a rapid HIV test at enrolment into the 
study in 2017. Budgetary constraints meant that women 
recruited in DREAMS cities were followed up at 12 months 
and 24 months after the initial enrolment survey, with 
women in non- DREAMS towns followed up at 24 months 
Key questions
What is already known?
 ► Young women who sell sex (YWSS) in Eastern and Southern Africa 
are at high risk of HIV.
 ► Available evidence shows that these women are less engaged with 
HIV prevention services.
 ► There are few evaluations of interventions for the broader popula-
tion of YWSS.
What are the new findings?
 ► We found higher engagement with clinical services among wom-
en in the places where DREAMS investments were made and dif-
ferences in pre- exposure prophylaxis (PrEP) use between women 
recruited in the Determined, Resilient, Empowered, AIDS- free, 
Mentored and Safe (DREAMS) cities and non- DREAMS towns, at 
24- month follow- up.
 ► After 24 months of follow- up, HIV incidence was high in both groups, 
and lower in DREAMS cities but with weak statistical evidence of a 
difference between the two groups.
 ► We found evidence for an impact on some secondary outcomes, 
including condom use, violence and number of partners, and some 
lessons for implementation.
 ► Overall, YWSS reported little uptake of social protection services.
 ► Implementation challenges, including limited experience of im-
plementing partners working with general populations in working 
with YWSS and barriers faced by YWSS in accessing these general 
population services, need to be addressed to improve coverage of 
combination HIV prevention services.
What do the new findings imply?
 ► The available evidence indicates the continued need to implement 
and evaluate combination HIV prevention services for YWSS, includ-
ing women who do not identify as sex workers.
 ► Further efforts are needed to identify approaches that enhance 
access to social protection services among YWSS combined with 
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only. In 2019, at 24- month follow- up, study participants 
were re- interviewed and offered HIV testing as before. 
Complementary strategies were implemented to retain 
women in the study in the DREAMS and non- DREAMS 
groups, including WhatsApp messaging, outreach activ-
ities and engaging YWSS who recruited women to the 
study to inform women about the study follow- up.
HIV testing procedures
At enrolment and follow- up, women were offered coun-
selling and HIV testing services using a serial HIV testing 
algorithm adapted from Zimbabwe's national testing 
and counselling guidelines. Determine HIV-1/2 or First 
Response HIV-1-2 kit antibody testing was used as the first 
screening test. Where the result was HIV positive, this was 
confirmed using First Response HIV-1-2 kit or Determine 
HIV-1/2. Where the two test results were discordant, 
repeat testing was advised within 2 weeks. All women were 
given the results of their HIV test.
Primary and secondary outcomes
The primary outcome was incident HIV infection over 
the 24- month study period. The outcome was calculated 
as the number of new HIV infections divided by the total 
person- years of follow- up during the 24- month study 
period, among YWSS who tested HIV- negative at enrol-
ment. Selection of secondary outcomes reflected the 
hypothesised causal pathway for how DREAMS would 
reduce HIV incidence (figure 1).5 We assessed thir-
teen prespecified, self- reported, secondary outcomes 
including condom- less sex with regular partners and 
clients, knowledge of HIV status of themselves and their 
partners, whether selling sex was the primary means by 
which women support themselves, number of recent 
clients and food insecurity.
As part of a broader process evaluation, we collected 
qualitative data at three time points during the trial 
from implementing partner staff and participants with 
varying levels of engagement in different DREAMS inter-
ventions. We conducted semi- structured interviews with 
14 implementing partner staff and 23 participants that 
explored perceptions and experiences of delivering or 
receiving DREAMS activities. We interviewed a further 17 
participants 2–3 times to identify barriers and facilitators 
to engaging with the programme over time.
Statistical analysis
In line with DREAMS targets, the study was powered 
to detect a 40% or greater reduction in HIV incidence 
after 24 months, assuming that HIV incidence in the 
comparison group would be 5.0%–8.0% per annum, as 
suggested by previous studies in Zimbabwe.5 Our anal-
ysis followed a prespecified analysis plan (online supple-
mental appendix 1).
We compared sociodemographic characteristics of 
enrolled YWSS by site and study group, including HIV 
status. We presented a flow diagram to illustrate enrol-
ment and retention in the study at 24- month follow- up, 
and examined patterns of retention by age, marital status, 
highest level of education attained and whether women 
self- identified as FSW, all measured at enrolment. Using 
data at 24- month follow- up, we described self- reported 
uptake of DREAMS- related services in all sites and used 
logistic regression adjusted for age and site to compare 
uptake between groups.
Reflecting the non- randomised study design, we identi-
fied potential confounding factors to adjust for to obtain 
the fairest comparisons between the two study groups at 
endline. Critically, HIV prevalence at enrolment differed 
between the two study groups. Using factors considered a 
priori as associated with HIV prevalence at enrolment or 
likely to be associated with HIV incidence,2 5 including age, 
educational attainment, marital status, self- identification 
Figure 1 DREAMS core package of interventions and the expected changes in behaviours and experiences (secondary 
outcomes). DREAMS, Determined, Resilient, Empowered, AIDS- free, Mentored and Safe; FSW, female sex workers; GBV, 
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as a FSW, STI symptoms and number of sexual partners 
in the past month, we used logistic regression to model 
predictors of HIV prevalence at enrolment. We found 
that these factors, which differed between the two study 
groups, were associated with HIV prevalence. Adjusting 
for these factors reduced the difference in HIV preva-
lence at enrolment across both study groups. We there-
fore decided a priori to adjust for these individual- level 
factors in our primary analysis and to add a linear term 
for community- level HIV prevalence.
Primary analysis was based on the intention- to- treat prin-
ciple, comparing cohorts recruited in the two DREAMS 
cities and four non- DREAMS towns regardless of partic-
ipants’ individual- level engagement with services. We 
calculated HIV incidence and the prevalence of secondary 
outcome measures for each study site. We pooled the 
data across study sites and used Poisson regression with 
follow- up time estimated as the time between interview 
dates, or half of this for women who seroconverted. We 
first conducted an age- adjusted analysis comparing HIV 
incidence between the DREAMS cities and non- DREAMS 
towns, and subsequently conducted a fully adjusted anal-
ysis including the confounders listed above.
For secondary outcomes, we used logistic regression 
adjusted for confounders listed above and for each 
respective secondary outcome measured at enrolment. 
In these analyses, where <5 women reported the outcome 
in a site, we used Fisher’s exact test.
Our primary analysis excluded data collected from 
women followed up at 12 months post- enrolment in the 
DREAMS cities. In sensitivity analysis, we included this 
data. If a woman seroconverted by the 12- month follow- up 
survey, we placed the seroconversion date at the mid- 
point between enrolment and 12 months. If a woman 
seroconverted between the 12- month and 24- month 
follow- up surveys, we placed the seroconversion date at 
the mid- point between these surveys.
In a second sensitivity analysis, we applied the principles 
of the RDS- II method, dropping seed participants from 
the analysis and weighting responses for each woman by 
the inverse of her self- reported network size at baseline 
(ie, the number of other YWSS she could have recruited 
to the study).9 In our protocol paper, we described that 
a full statistical analysis plan would be developed before 
unblinding the data, but also suggested that our analysis 
would apply RDS weighting.5 During the development 
of the plan, but before looking at the data, we decided 
against the use of weighting in the primary analysis for the 
following reasons: the aim of our approach was to recruit 
balanced cohorts of YWSS in DREAMS and non- DREAMS 
sites and pool these for analysis, not to generate statistics 
representative of the cities or towns; the primary analysis 
was to be conducted only among the subset of women 
who were HIV- negative at enrolment and followed up 
successfully and therefore weighting may not be appro-
priate; and an unweighted analysis is simpler and more 
transparent, and is recommended in Poisson regression 
analyses of RDS data.10
Thirdly, assuming a uniform distribution and using 
50 imputations, we randomly imputed the seroconver-
sion date as a fraction of the interval between enrolment 
and 24- month survey dates, among women who serocon-
verted by the 24- month follow- up survey.11 12
Patient and public involvement
FSW work closely with the research team at the Centre 
for Sexual Health and HIV/AIDS Research, Zimbabwe, 
however, were not directly involved in the development 
of the research questions and design of the study. FSW 
helped design and implement social mapping to identify 
YWSS hotspots to guide survey processes and to support 
RDS. YWSS were integrally involved in running all aspects 
of the DREAMS implementation for YWSS.
Role of funding source
The Bill & Melinda Gates Foundation staff reviewed and 
provided non- binding comments on the protocol and 
study analysis plan, but had no role in data collection, 
data analysis, data interpretation or writing of the report. 
The corresponding author had full access to all the data 
in the study and had final responsibility for the decision 
to submit for publication.
RESULTS
Study participants
Between April and July 2017, we enrolled 2431 women 
(1204 in DREAMS cities and 1227 in non- DREAMS 
towns). Nineteen women had missing HIV test data. 
Among the remaining women, 76% (n=1859) tested HIV 
negative at enrolment (963, 80.0%, in DREAMS cities 
and 896, 73.0%, in non- DREAMS towns; figure 2). HIV 
prevalence was higher in the four non- DREAMS towns 
compared with the two DREAMS cities (26.3%, n=320 vs 
19.5%, n=234; table 1 & online supplemental appendix 
2 table 1).
Among women testing HIV negative at enrolment, 
women recruited in the DREAMS cities reported higher 
levels of educational attainment, were less likely to be 
separated/divorced and a higher proportion reported 
selling sex for ≥3 years compared with women in the non- 
DREAMS towns (table 1). Women in non- DREAMS towns 
reported lower levels of condom- less sex with clients and 
condom use with regular partners at last sex (online 
supplemental appendix 2 tables 1 and 2).
Participant retention and follow-up
At 24- month follow- up, 1019 (54.8%) women testing HIV 
negative at enrolment were retained in the study (55.9%, 
n=538 in DREAMS cities; 53.7%, n=481 in non- DREAMS 
towns; figure 2). The mean follow- up time across all sites 
was 1.86 person- years (range in DREAMS cities: 1.76–
1.90 person- years; non- DREAMS towns range: 1.83–1.97 
person- years).
Enrolment characteristics and behaviours across 
the two groups were similar among women retained at 
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table 3). Retained women were similar to women lost to 
follow- up in terms of marital status, educational attain-
ment and whether they self- identified as FSW or not at 
enrolment (online supplemental appendix 3 table 4). In 
non- DREAMS towns, a lower proportion of YWSS aged 
18–19 were retained (49.7%, n=185) compared with 
DREAMS cities (57.6%, n=208; p=0.046).
Uptake of services available through the DREAMS partnership
Uptake of and access to clinical services were higher 
in DREAMS cities than non- DREAMS towns (table 2). 
In DREAMS cities, women were more likely to report 
accessing clinics targeting FSW (58.9%, n=317/538 vs 
28.3%, n=136/480), seeing condom promotion activities 
(67.4%, n=361/536 vs 53.0%, n=254/479) and attending 
community mobilisation activities (13.6%, n=73/537 vs 
5.6%, n=27/480).
Participation in savings and loans groups and cash 
transfers was low, with little difference between women 
in DREAMS cities and non- DREAMS towns (table 2). In 
qualitative data, we found that this partly reflected delays 
in establishing the YWSS component of the programme. 
In the early stages, service providers struggled to under-
stand the specific needs of YWSS and felt uncomfort-
able integrating them with other youth. Many social 
programmes were fully enrolled prior to YWSS seeking 
to join, as implementing partners reached targets quickly 
from the broader population of young women. Over 
time, additional places were made available and priori-
tised for YWSS, although those delivering the services did 
not always have experience of working with this vulner-
able group:
I think that was one of the issues that really made it dif-
ficult for us in terms of layering services because you see 
that there was much demand within our cohort of clients 
that would have wanted that service, but then that service 
was not available. … and issues to do with adolescents and 
young women selling sex are on the sensitive side. If you 
don’t have the skills, you will not be able to identify a large 
group of them [to recruit into the programme]. (Imple-
menting Partner, Site A)
When YWSS did engage in opportunities, they some-
times felt stigmatised. We received reports of returning 
school pupils being publicly identified as ‘sex workers,’ 
denied access to the library, or made to sit outside class-
rooms and observe teaching through open windows:
Some [other children] will be saying, ‘why have you come 
to school? Why did you leave your work of selling sex?’ to 
make a scene in front of other people. … at times I felt so 
ashamed and I would feel it’s better not to go there. (18 
years, Site B)
Other barriers stemmed from YWSS’ entrenched 
poverty, which meant they could not easily devote time to 
Figure 2 Consolidated Standards of Reporting Trials flow diagram of young women who sell sex recruited to the study and 
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their studies, needing to earn money or look after family 
members. There were also additional costs such as bus 
fares and purchasing supplies for vocational training that 
YWSS could not afford. Other barriers to uptake included 
competing demands on YWSS’ time, that is, caring for 
siblings, and their inability to pay for costs associated with 
participation, such as transport to classes or uniforms 
and equipment required for vocational training. These 






Comparison p valuen/N (%) n/N (%)
Age at recruitment 0.076
  18–19 361/963 (37.5) 372/896 (41.5)
  20–24 602/963 (62.5) 524/896 (58.5)
Highest level of education <0.001
  None/incomplete primary 28/963 (2.9) 77/896 (8.6)
  Complete primary 61/963 (6.3) 92/896 (10.3)
  Incomplete secondary 817/963 (84.8) 707/896 (78.9)
  Complete secondary or higher 57/963 (5.9) 20/896 (2.2)
Marital status <0.001
  Single/never married 668/963 (69.4) 497/896 (55.5)
  Married/living together as if married 21/963 (2.2) 16/896 (1.8)
  Divorced/separated 270/963 (28.0) 379/896 (42.3)
  Widowed 4/963 (0.4) 4/896 (0.4)
Years selling sex 0.001
  0–2 508/962 (52.8) 538/893 (60.2)
  3+ 454/962 (47.2) 355/893 (39.8)
Self- identification as sex worker 0.847
  No 319/952 (33.5) 302/890 (33.9)
  Yes 633/952 (66.5) 588/890 (66.1)
Condom use at last with regular partner 0.002
  No 252/739 (34.1) 294/696 (42.2)
  Yes 487/739 (65.9) 402/696 (57.8)
Condom- less sex with regular partner in the past 
month
0.478
  No 415/740 (56.1) 379/699 (54.2)
  Yes 325/740 (43.9) 320/699 (45.8)
Condom use at last with client 0.477
  No 86/743 (11.6) 65/627 (10.4)
  Yes 657/743 (88.4) 562/627 (89.6)
Condom- less sex with client in the past month 0.001
  No 611/745 (82.0) 555/628 (88.4)
  Yes 134/745 (18.0) 73/628 (11.6)
STI symptoms in the last 12 months 0.067
  No 775/963 (80.5) 690/896 (77.0)
  Yes 188/963 (19.5) 206/896 (23.0)
Risk of common mental disorder <0.001
  No 595/963 (61.8) 624/896 (69.6)
  Yes 368/963 (38.2) 272/896 (30.4)
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(N=481) DREAMS vs non- DREAMS
n/N (%) n/N (%) OR (95% CI) P value
Direct HIV prevention and clinical services
Recently HIV tested (within 6 months prior to the survey)
  No 181/537 (33.7) 152/478 (31.8)
  Yes 356/537 (66.3) 326/478 (68.2) 1.32 (0.83 to 2.10) 0.237*
Ever been offered PrEP
  No 285/538 (53.0) 476/481 (99.0)
  Yes 253/538 (47.0) 5/481 (0.9) – <0.001†
Current use of contraceptive methods (including condom)
  No 61/495 (12.3) 101/432 (23.4)
  Yes 434/495 (87.7) 331/432 (76.6) 1.37 (0.71 to 2.63) 0.343*
Attendance to Sisters with a Voice clinic in past 12 months
  No 221/538 (41.1) 344/480 (71.7)
  Yes 317/538 (58.9) 136/480 (28.3) 12.51 (6.90 to 22.69) <0.001*
Saw condom promotion activities in the past 12 months
  No 175/536 (32.6) 225/479 (47.0)
  Yes 361/536 (67.4) 254/479 (53.0) 1.91 (1.22 to 3.00) 0.005*
Attendance to Sisters with a Voice community mobilisation meeting in past 12 months
  No 464/537 (86.4) 453/480 (94.4)
  Yes 73/537 (13.6) 27/480 (5.6) 22.76 (3.09 to 167.71) 0.002*
Social and economic protection services
Receipt of cash transfer or educational subsidy in past 12 months
  No 516/538 (95.9) 480/480 (100.0)
  Yes 22/538 (4.1) 0/480 (0.0) – <0.001†
Participation in continuing education programme in past 12 months
  No 528/538 (98.1) 480/480 (100.0)
  Yes 10/538 (1.9) 0/480 (0.0) – 0.002†
Participation in job preparation training in past 12 months
  No 529/538 (98.3) 480/480 (100.0)
  Yes 9/538 (1.7) 0/480 (0.0) – 0.004†
Participation in apprenticeship in past 12 months‡
  No 538/538 (100.0) 480/480 (100.0)
  Yes 0/538 (0.0) 0/480 (0.0) – –
Participation in internal savings and loan group in past 12 months
  No 514/537 (95.7) 479/479 (100.0)
  Yes 23/537 (4.3) 0/479 (0.0) – <0.001†
Gender- based violence care and support services
Accessed healthcare services after experiencing GBV in past 12 months§
  No 49/63 (77.8) 40/48 (83.3)
  Yes 14/63 (22.2) 8/48 (16.7) 1.38 (0.15 to 10.05) 0.832*
Provided with shelter in past 12 months (among women experiencing GBV)
  No 188/189 (99.5) 181/183 (98.9)
  Yes 1/189 (0.5) 2/183 (1.1) – 0.549†
*Age and site adjusted Wald test p value.
†Fisher’s exact p value—OR and 95% CI could not be estimated using logistic regression due to sparse data.
‡Fisher’s exact p value or OR and 95% CI could not be estimated due to sparse data.
§Among YWSS who experienced sexual violence.
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challenges meant that YWSS had limited ability to access 
‘layered’ services as intended.
HIV incidence rate by study group and site
Overall, 79 YWSS HIV seroconverted after 24 months. 
HIV incidence was 3.60/100 person- years in DREAMS 
Site A and 2.76/100 person- years in DREAMS Site B. In 
non- DREAMS towns, the rate of new infections ranged 
from 4.28/100 person- years to 7.07/100 person- years 
(table 3).
HIV incidence among YWSS in DREAMS cities was 
3.1/100 person- years compared with 5.3/100 person- 
years among YWSS in non- DREAMS towns (RR=0.59; 
95% CI 0.38 to 0.93). In our primary analysis, adjusting 
for confounding variables, HIV incidence was lower in 
DREAMS cities than in non- DREAMS towns, but with 
weak statistical evidence of a difference (adjusted rate 
ratio (RR)=0.68; 95% CI 0.40 to 1.19; p=0.18) (table 3).
In a sensitivity analysis, including data from women 
in DREAMS cities followed up at 12 months, we found 
a very similar result (adjusted RR=0.79, 95% CI 0.47 to 
1.32; p=0.36; online supplemental appendix 6 table 8). 
When we applied the principles of RDS- II methodology, 
the intervention effect was larger, the point estimate 
exceeded the 40% incidence reduction hypothesised 
by DREAMS, and the result was of borderline statis-
tical significance (adjusted RR=0.55, 95% CI 0.28 to 
1.08; p=0.08; online supplemental appendix 6 table 9). 
Randomly imputing the seroconversion date gave results 
identical to using the mid- point as seroconversion date 
(online supplemental appendix 6 table 10).
Secondary outcomes by study group and site
Compared with women in the non- DREAMS towns, 
YWSS in the DREAMS cities were more likely to report 
ever having used PrEP (28.1%, n=151/538 vs 0.6%, 
n=2/481; table 4). In DREAMS cities, 11.5% (62/538) of 
YWSS reported current use of PrEP at 24 months, with 
no YWSS in non- DREAMS towns reporting current PrEP 
use. Despite higher self- reported use of PrEP in DREAMS 
cities, we found that within those cities there were a 
similar percentage of HIV infections between YWSS who 
did and did not report having ever used PrEP (4.6%, 
n=7/151 vs 6.2%, n=24/387) and current use of PrEP was 
low. Additionally, PrEP use among YWSS who reported 
condom- less sex with a client or regular partner in the 
past month was very low (11.4%, n=31/273).
More women in the DREAMS cities reported the 
ability to negotiate condom use (92.6%; n=498/538 vs 
81.0%, n=389/480; adjusted OR=3.39 95% CI 2.24 to 
5.14; table 4). Women in DREAMS cities were less likely 
to report condom- less sex with clients (11.2%, n=60/535 
vs 17.2%, n=82/478; adjusted OR=0.58 95% CI 0.38 to 
0.89) and having had more than three clients in the 
past month (47.3%, n=254/537 vs 56.6%, n=265/468; 
adjusted OR=0.66 95% CI 0.50 to 0.87). Fewer women in 
DREAMS cities reported experiencing violence from part-
ners in the past 12 months (19.3%, n=104/538 vs 28.3%, 
Table 3 HIV incidence among young women who sell sex testing HIV negative at enrolment, by arm (A) and site (B) (N=1017)
Number of 
seroconversions/
person- years of 
follow- up
Rate per 100 person- 
years (95% CI)
Age- adjusted rate 
ratio (95% CI) p value
Fully adjusted rate 
ratio (95% CI)* p value
(A) Comparison of HIV incidence among YWSS testing HIV negative at enrolment, by arm
Non- DREAMS (N=479) 48/907.62 5.29 (3.99 to 7.02) 1.0 1.0
DREAMS (N=538) 31/988.14 3.14 (2.21 to 4.46) 0.59 (0.38 to 0.93) 
p=0.022
0.68 (0.40 to 1.19) 
p=0.176
(B) Comparison of HIV incidence among YWSS testing HIV negative at enrolment, by site
DREAMS Site A 
(n=252)
16/444.74 3.60 (2.20 to 5.87) 1.0   
DREAMS Site B 
(n=286)
15/543.40 2.76 (1.66 to 4.58) 0.75 (0.37 to 1.52) 
p=0.420
0.68 (0.33 to 1.43) 
p=0.313
Non- DREAMS Site C 
(n=121)
16/226.24 7.07 (4.33 to 11.54) 1.93 (0.96 to 3.88) 
p=0.063
1.56 (0.74 to 3.29) 
p=0.243
Non- DREAMS Site D 
(n=102)
11/192.90 5.70 (3.16 to 10.30) 1.57 (0.73 to 3.38) 
p=0.252
1.33 (0.58 to 3.03) 
p=0.503
Non- DREAMS Site E 
(n=141)
12/278.41 4.31 (2.45 to 7.59) 1.21 (0.57 to 2.56) 
p=0.617
1.04 (0.46 to 2.38) 
p=0.923
Non- DREAMS Site F 
(n=115)
9/210.07 4.28 (2.23 to 8.23) 1.16 (0.51 to 2.63) 
p=0.723
1.00 (0.43 to 2.34) 
p=0.996
*Adjusted for age, highest level of education attained, marital status, self- identification as female sex workers, STI symptoms, number of 
sexual partners in the past month, HIV prevalence (measured at enrolment).
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towns DREAMS vs non- DREAMS
(N=538) (N=481) Age- adjusted Fully adjusted*
n/N (%) n/N (%) OR (95% CI) P value OR (95% CI) P value
Improved access to clinical services and HIV prevention services
Knowledge of HIV status
  No 119/538 (22.1) 118/481 (24.5)
  Yes 419/538 (77.9) 363/481 (75.5) 1.15 (0.86 to 1.54) 0.358 1.22 (0.90 to 1.66) 0.197
Ever taken PrEP
  No 378/538 (71.9) 478/481 (99.4)
  Yes 151/538 (28.1) 3/481 (0.6) 62.22 (19.69 to 196.62) <0.001 63.82 (19.78 to 205.90) <0.001
Ability to negotiate condom use with any partner
  No 40/538 (7.4) 91/480 (19.0)
  Yes 498/538 (92.6) 389/480 (81.0) 2.92 (1.97 to 4.34) <0.001 3.39 (2.24 to 5.14) <0.001
Knowledge of the HIV status of at least one of their three most recent partners
  No 179/528 (33.9) 210/474 (44.3)
  Yes 349/528 (66.1) 264/474 (55.7) 1.55 (1.20 to 2.00) 0.001 1.38 (1.06 to 1.81) 0.018
Condom- less sex with regular partner in the past month
  No 275/536 (51.3) 199/478 (41.6)
  Yes 261/536 (48.7) 294/478 (58.4) 0.68 (0.53 to 0.87) 0.002 0.72 (0.53 to 0.98) 0.034
Condom- less sex with client in the past month
  No 475/535 (88.8) 396/478 (82.8)
  Yes 60/535 (11.2) 82/478 (17.2) 0.61 (0.43 to 0.87) 0.007 0.58 (0.38 to 0.89) 0.013
Accessed STI treatment services in the past 12 months†
  No 7/74 (9.5) 18/93 (19.4)
  Yes 67/74 (90.5) 75/93 (80.6) 2.36 (0.92 to 6.03) 0.073 – –
Improved coverage of social and economic protection service
Food insecurity
  No 367/538 (68.2) 295/479 (61.6)
  Yes 171/538 (31.8) 184/479 (38.4) 0.75 (0.58 to 0.97) 0.027 0.81 (0.61 to 1.07) 0.130
Selling sex is the main way to support myself
  No 196/538 (36.4) 159/479 (33.2)
  Yes 342/538 (63.6) 320/479 (66.8) 0.87 (0.67 to 1.13) 0.284 0.93 (0.71 to 1.22) 0.585
Ever been unable to decline sex in the past month
  Never/not in the past 
month
257/534 (48.1) 236/474 (49.8)
  At least once in the 
past month
277/534 (51.9) 238/474 (50.2) 1.07 (0.83 to 1.37) 0.595 1.05 (0.81 to 1.36) 0.689
Number of sex work clients in the past month
  ≤3 283/537 (52.7) 203/468 (43.4)
  >3 254/537 (47.3) 265/468 (56.6) 0.68 (0.53 to 0.88) 0.003 0.66 (0.50 to 0.87) 0.003
Gender- based violence prevention, and care and support services
Experience of violence from partners in the past 12 months
  No 434/538 (80.7) 345/481 (71.7)
  Yes 104/538 (19.3) 136/481 (28.3) 0.61 (0.45 to 0.81) 0.001 0.64 (0.47 to 0.87) 0.005
Experience of violence from police in the past 12 months
  No 531/538 (98.7) 473/479 (98.7)
  Yes 7/538 (1.3) 6/479 (1.3) 1.04 (0.35 to 3.11) 0.070 1.01 (0.32 to 3.16) 0.982
Bold values highlight significant results.
*Adjusted for age, highest level of education attained, marital status, self- identification as female sex workers (measured at baseline), and for each respective secondary outcome 
measured at enrolment.
†Adjusted OR and 95% CI could not be estimated using logistic regression due to sparse data.
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n=136/481; adjusted OR=0.64 95% CI 0.47 to 0.87). We 
found little evidence for differences in other secondary 
outcomes, including whether the YWSS’ primary means 
of support was sex work, and their ability to decline sex.
Secondary outcomes varied across sites and, for some 
outcomes, were not always in the direction expected 
(online supplemental appendix 4 table 5). For example, 
condom- less sex with client in the past month in two non- 
DREAMS towns (8.0%, n=8/100 and 10.7%, n=13/122) 
was lower or similar to levels reported by women in 
DREAMS cities. Similarly, the ability to negotiate condom 
use in these two non- DREAMS towns (92.6% n=113/122 
and 85.3% n=87/102) was higher than or similar to levels 
reported in each DREAMS city.
DISCUSSION
After 24 months of follow- up, we found that HIV inci-
dence was lower among YWSS recruited in two Zimba-
bwean cities implementing the DREAMS programme 
than in four towns where DREAMS was not imple-
mented. After adjustment for baseline imbalance in HIV 
prevalence and predictors of HIV incidence, this poten-
tial effect of DREAMS on HIV incidence was not statisti-
cally significant. We identified some changes in outcomes 
on important ‘pathways to impact’: YWSS recruited in 
DREAMS cities reported fewer clients in the past month, 
less condom- less sex in the last month and higher levels 
of PrEP use at 24- month follow- up; yet we found little 
difference in women’s engagement with social protec-
tion services. Despite our null finding, it remains plau-
sible that DREAMS investments may have contributed to 
reduced HIV incidence among YWSS through increased 
access to clinical HIV prevention services, including PrEP 
and condoms.
Our study had limitations, most of which we were aware 
of from the start.5 We considered this study a plausibility 
evaluation since it was only powered to detect a large 
difference in HIV incidence and because of the lack of 
randomisation. A 40% reduction in HIV incidence over 
24 months was an ambitious target and full implemen-
tation was not achieved until early 2019. Our sample 
size calculation estimated 70% retention of recruited 
women, but in practice this was lower, likely affecting the 
study’s power to detect any difference in HIV incidence 
as well as potentially introducing bias.5 Mobility is high 
among FSW in Zimbabwe, including YWSS, and during 
efforts to maintain contact with enrolled women we often 
heard that they had left the area to seek employment 
opportunities.
We used data collected by the national FSW programme 
to identify comparison sites similar to the DREAMS 
cities based on, among other factors, attendance to the 
programme and the proportion of attendees aged 18–24.5 
With the DREAMS cities among the largest and most 
populous in Zimbabwe, identifying comparison sites was 
challenging, as evidenced by the higher HIV prevalence 
in these towns at enrolment. Also, service delivery was 
less intense and delivered through mobile clinics in all 
but one non- DREAMS towns, compared with DREAMS 
cities. The confounding factors, for which we adjusted 
for in our primary analysis, reduced but did not elimi-
nate differences in HIV prevalence at enrolment. There 
may, therefore, be other factors that we did not account 
for that could explain the variation in HIV incidence. 
Furthermore, although incidence was lower in the two 
DREAMS cities than in all four non- DREAMS towns, it 
varied across the few sites included in our study, limiting 
our ability to draw firm conclusions about any effect of 
DREAMS on HIV incidence.
Finally, our secondary outcomes were self- reported 
via face- to- face- interviews and thus potentially prone to 
social desirability bias and the potential for an ‘inter-
vention’ effect of more frequent contact and follow- ups 
among the YWSS in DREAMS cities over time.
Intriguingly, in a sensitivity analysis where we dropped 
seed participants and applied RDS- II weighting, we found 
a borderline significant impact of the programme aligned 
with the 40% reduction hypothesised. We decided a 
priori not to use this weighting in the primary analysis, 
and consider interpretation of these findings complex, 
but report them for transparency. At enrolment, RDS 
diagnostics suggested that women recruited were repre-
sentative of the network of YWSS in the majority of sites, 
but convergence was not realised in one of the smaller 
non- DREAMS towns suggesting that YWSS may not have 
been representative of the broader network of YWSS in 
this site.2 Furthermore, documenting refusal rates is diffi-
cult in RDS design.13
Despite these limitations, our study provides invaluable 
and important evidence in relation to HIV prevention 
efforts for a critical population. Despite their vulnera-
bility, YWSS are often underrepresented in research.2 14 
We show that, although challenging, cohort studies with 
YWSS are feasible. Retention was affected by women’s 
mobility and likely affected by some women transitioning 
out of sex work, and therefore no longer interested in 
participation. Nonetheless, we retained over half the 
~2400 women across six sites over the course of the study. 
Although retention was low compared with a cohort 
study of young FSW in Burkina Faso, which retained 86% 
of 321 women recruited over a median of 16.8 months 
of follow- up,15 and a study in Tanzania, which retained 
78% of 293 HIV- negative FSW through monthly contacts 
over 18 months,16 there was little evidence of differential 
follow- up between arms in our study. To retain women, 
future cohort studies with YWSS should similarly employ 
a combination of complementary strategies, including 
use of mobile phone messaging and outreach.
Our findings of a plausible effect of DREAMS, adds an 
important new finding to a small overall evidence base. 
In Burkina Faso, a cohort study combined with modelling 
found a significant effect of integrated prevention and 
care services combined with peer- led education sessions 
on HIV incidence among young FSW.15 In Benin, a time- 
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condom use and empower FSW, combined with clinical 
services and strategies to reduce violence, found a signif-
icant impact on HIV prevalence.17 In Tanzania, Project 
Shikamana found that community- led peer educa-
tion, peer navigation, sensitivity training for HIV care 
providers and a community- led drop- in centre for activi-
ties to promote social cohesion significantly reduced HIV 
incidence among FSW.16 Similar to our study, Project 
Shikamana included a small number of sites (N=2), 
limiting their ability to draw inferences of impact at 
scale.16 Unlike most of these studies, our target popula-
tion included all YWSS in the DREAMS cities, including 
those who did not identify as FSW, and the intervention 
included components delivered outside of health facility 
settings by numerous implementing partners.
Although HIV incidence was lower among YWSS in 
DREAMS cities, HIV incidence was high in all sites. Our 
study reiterates that more needs to be done to strengthen 
implementation of evidence- based HIV prevention inter-
ventions for YWSS. YWSS, both those who do and do 
not self- identify as FSW, are often missed by research 
and programmes.2 14 18 Engaging younger peer outreach 
workers and specifically targeting younger FSW can 
increase engagement,18 but uptake of programmes 
tailored to meet the needs of YWSS is often minimal.19 
Failure to strengthen prevention programming for 
YWSS, including young FSW, has implications for the 
health outcomes of women themselves and for broader 
HIV prevention efforts.
PrEP formed a component of the DREAMS core 
package. Current use of PrEP among women partici-
pating in our study was low at 24 months, consistent with 
findings reported by PrEP efficacy and implementa-
tion studies with AGYW, including FSW, in sub- Saharan 
Africa,20 21 and a number of women in DREAMS cities 
who initiated PrEP seroconverted. PrEP is an important 
prevention option for AGYW, providing an opportunity 
for greater autonomy and control over sexual health.22 
Recent PrEP studies and our findings underscore the 
need for approaches to support PrEP initiation and 
adherence to PrEP during periods of use,23 particularly 
among the many women in our study who reported 
condom- less sex. Stigma, norms and sexual partners have 
been shown to influence PrEP use and adherence.24 25 
Recognising that PrEP and condom use are influenced 
by women’s broader social environment, HIV preven-
tion programmes need to be holistic in their approach, 
understanding the reasons underlying poor adherence 
and providing social support and evidence- based adher-
ence support during periods of PrEP use. Lessons learnt 
from effective antiretroviral therapy (ART) adherence 
strategies could inform PrEP adherence support. Wrap-
around peer- supported community- based treatment 
improved viral suppression among adolescents aged 
13–19 in Zimbabwe,26 and long- term virological suppres-
sion was achieved among adults attending treatment 
adherence clubs in South Africa.27 With evidence that 
long- acting PrEP is effective at reducing HIV risk among 
men who have sex with men and transgender women, 
ongoing development of alternative formulations of 
long- acting PrEP holds promise for addressing barriers 
to oral PrEP for AGYW.28 In addition to support for PrEP 
use, continued condom supply and strengthened distri-
bution alongside strategies to promote condom use, 
where feasible and when PrEP adherence is low, need 
continued support and scale- up.29
To reduce HIV incidence by 40% over 24 months, 
DREAMS endeavoured to provide AGYW with a combi-
nation of evidence- based HIV prevention interventions 
to address the multiple factors influencing HIV risk.30–32 
Termed ‘layering’, the intention was to provide AGYW 
multiple interventions from the DREAMS core package 
simultaneously.30 Studies show that ‘layering’ was 
achieved in other DREAMS- supported countries,31 yet 
we found that evidence of successful ‘layering’ of social 
services alongside comprehensive clinical services for 
FSW among this particular group of women in Zimbabwe 
was complex. At follow- up, coverage of clinical services 
and condoms was generally higher in the DREAMS 
cities than the four towns. However, coverage of social 
protection services was low among all women partici-
pating in the study. In DREAMS cities, low coverage was 
driven in part by implementation challenges, including 
the limited experience of other implementing partners 
in working with YWSS, and by barriers faced by YWSS in 
accessing these services. Lessons learnt through the early 
implementation and delivery of DREAMS to YWSS have 
been used to streamline service delivery for this group 
of women. There remains, therefore, scope to evaluate 
the influence of an adapted form of DREAMS, aimed at 
being more responsive to the needs of YWSS, on HIV risk 
among YWSS and learn how best to deliver wraparound 
social protection services to YWSS.
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INTRODUCTION 
Worldwide, especially in sub-Saharan Africa, young women are at high risk of HIV due to increased 
biological, economic and social vulnerability. In Zimbabwe, where the HIV burden is one of the 
highest in the world and HIV prevalence was 13.3% among adults aged 15-49 years in 2017,1 
adolescent girls and young women (AGYW) aged 15-24 years are at particularly high risk of HIV. 
Recognising the vulnerability of AGYW and the social, economic and biological factors that shape 
women’s risk, the DREAMS Partnership was developed to deliver a combined package of 
interventions targeted at AGYW, their partners, families and communities, to address the interacting 
factors that shape HIV risk among this particularly vulnerable population. One particular target 
population for the DREAMS Partnership was young women who sell sex (YWSS). In Zimbabwe, 
among this group, DREAMS included an offer of oral pre-exposure prophylaxis (PrEP), and condom 
promotion and provision. 
We conducted an impact evaluation of DREAMS among YWSS in Zimbabwe. 
AIM 
The aim of this study was to estimate the impact of the DREAMS combined package of HIV 
prevention interventions on HIV incidence among YWSS aged 18-24 years. We also sought to 
evaluate the impact of DREAMS on a number of secondary outcomes. 
STUDY DESIGN 
This study was a non-randomised plausibility design to estimate the effect of DREAMS on HIV 
incidence and other secondary outcomes, highlighted in section 5. 
We will compare HIV incidence among a cohort of YWSS recruited in two districts where DREAMS 
was being implemented and followed up over 2 years, to HIV incidence among a cohort of YWSS 
recruited in four districts where DREAMS was not being implemented and also followed up over 2 
years. A similar approach will be used for comparison of secondary outcomes. 
SAMPLING 
In the two DREAMS sites, a network-based recruitment strategy (respondent-driven sampling (RDS)) 
was used to identify YWSS in the study communities, offer them HIV testing services and then inform 
and refer these YWSS to treatment and prevention services, including PrEP and the DREAMS 
package of HIV prevention interventions through the national programme for sex workers ‘Sisters 
with a Voice’ and then onward to the full range of DREAMS services. This process was also used to 
recruit these women into the evaluation cohort. More specific details of the recruitment process are 
provided in the protocol (e.g. seed selection, wave recruitment procedures, remuneration). 
In two DREAMS sites, eligible YWSS were asked for written informed consent to be interviewed at 
enrolment into the study in 2017, and then followed-up at 12 and 24 months after the initial 
enrolment survey. At each time point, rapid HIV testing and counselling was offered to YWSS to 
ascertain the HIV status of the study participants. A detailed working definition of YWSS is provided 
in the protocol, but we note here that we included both young women who did and did not self-
identify as sex workers, anticipating that the outcome profile might differ among these two groups 
of young women. 
The same network-based recruitment strategy was used to identify and recruit a cohort of YWSS in 
the four non-DREAMS districts. YWSS recruited in these four districts were also offered HIV 
counselling and testing services and were referred to the existing national HIV programme for sex 
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Global Health
 doi: 10.1136/bmjgh-2020-003892:e003892. 6 2021;BMJ Global Health, et al. Chabata ST
3 
workers, run by the Centre for Sexual Health and HIV/AIDS Research (CeSHHAR). Through this 
programme they could access HIV prevention services, including condoms, STI treatment and health 
education, but did not have access to PrEP or other initiatives offered under the DREAMS 
Partnership. These YWSS were recruited during the same time frame as women in the two DREAMS 
districts, and were interviewed at enrolment and followed up at 24-months post-enrolment. 
Although planned, no follow up was done at 12 months among this group due to budgetary 
constraints. 
The difference, therefore, between DREAMS and non-DREAMS sites was that, in DREAMS sites, 
YWSS had access to comprehensive SRH and HIV services through the Sisters programme PLUS 
access to PrEP and other DREAMS services, such as social protection interventions. In the non-
DREAMS sites, YWSS had access to comprehensive SRH and HIV services through the ‘Sisters’ 
programme but were not referred for PrEP / other DREAMS services. 
PRIMARY AND SECONDARY OUTCOMES 
The primary outcome is incident HIV infection over the 24-month study period, defined as: 
Number of new HIV infections among YWSS who tested HIV-negative at enrolment / 
Total person-years of follow-up accumulated during the 24-month study period. 
Measurement of the primary outcome was restricted to women testing HIV negative at enrolment 
and followed-up 24-months post-enrolment. HIV status at each round was ascertained through the 
rapid HIV tests delivered during the counselling and testing process with results returned to 
participants. No confirmatory testing procedures were conducted for the purpose of the impact 
evaluation. 
Person-years of follow-up was defined as the total follow-up time between the enrolment survey in 
2017 and the follow-up survey 24 months after enrolment (2019). For women who seroconverted 
during the study, the time of seroconversion was set as the mid-point between the enrolment 
survey and follow-up at 24 months. 
The secondary objective of the impact evaluation is to explore whether the DREAMS package of 
interventions had an impact on the on the secondary outcomes listed in Table 1 and in line with the 
hypothesised causal pathway through which the DREAMS package of interventions would reduce 
HIV incidence (Figure 1). 
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Table 1. Definition of secondary outcomes 
Secondary outcome Definition Denominator Numerator 
Biological protection 
Knowledge of HIV status [Composite outcome] Proportion of YWSS who have EITHER (i) 
ever tested HIV-positive OR (ii) had an HIV test during the past 
6 months and report their HIV-negative result 
All YWSS participating in the survey 
at 24-month follow-up  
YWSS reporting HIV testing in previous 6 months or 
self-reporting their HIV positive status 
Coverage of PrEP Proportion of HIV negative YWSS who are currently taking 
PrEP 
YWSS not testing HIV-positive at 24-
month follow up 
Number of YWSS self-reporting their HIV-negative 
status who self-report currently taking PrEP 
Uptake of PrEP Proportion of HIV negative women who were offered PrEP 
who accepted the offer 
YWSS self-reporting ever being 
offered PrEP 
Number of YWSS self-reporting that they were ever 
offered PrEP AND that they accepted the offer of 
PrEP  
Knowledge of partner’s status Proportion of YWSS who report knowing the HIV status of at 
least one of their three most recent partners 
All YWSS participating in the 24-
month follow up survey 
Number of YWSS who report knowing the HIV status 
of at least one of their three most recent partners 
 Proportion of YWSS who report feeling confident in discussing 
HIV testing with any partner 
All YWSS participating in the 24-
month follow up survey 
Number of YWSS who agree/strongly agree that they 
can discuss HIV testing with any partners 
Condom-less sex with regular partner Proportion of YWSS who report condom-less sex with regular 
partner in the past month 
All YWSS participating in the 24-
month follow up survey 
Number of YWSS reporting any condom less sex with 
regular partner in the past month 
Condom-less sex with client Proportion of YWSS who report condom-less sex with client in 
the past month 
All YWSS participating in the 24-
month follow up survey 
Number of YWSS reporting any condom less sex with 
client in the past month 
Increased ability to negotiate condom use with 
any partner 
Proportion of women agreeing that they feel confident in 
negotiating condom use with any partner 
All YWSS participating in the 24-
month follow up survey 
Number reporting that they agree/strongly agree 
that they are confident in negotiating condom use 
with any sexual partner  
Number of sex work clients  Number of partners with whom women had sex with in 
exchange for money/material support (i.e. clients) in the past 
month 
All YWSS participating in the 24-
month follow up survey 
Categorical variable of <3; 4-9; 9+ clients reported in 
the past month 
Access to STI treatment services Proportion of YWSS who self-reported having STI symptoms 
and seeking of treatment services or advice in the last 12 
months 
YWSS reporting having STI symptoms 
in the past 12 months among YWSS 
participating in the follow-up survey 
Number of YWSS reporting accessing treatment 
services or advice after having STI symptoms 
Social Protection 
Food insecurity [Composite outcome] Proportion of YWSS who IN THE PAST 4 
WEEKS have EITHER (i) had no food to eat because of lack of 
resources to get food OR (ii) had a household member who 
went to bed hungry because there was not enough food OR 
(iii) had a household member who had a whole day and night 
without food 
All YWSS participating in the 24-
month follow up survey 
Number of YWSS responding ‘Yes’ to either of the 
three questions on inadequate quantity of food 
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Reliance on sex work for economic reasons Proportion of YWSS who report that they were unable to 
decline sex with a man because of support offered in the past 
month 
All YWSS participating in the 24-
month follow up survey 
Number of YWSS reporting ever unable to decline 
sex in past month 
 Proportion of YWSS who report that selling sex is the main 
way they support themselves 
All YWSS participating in the 24-
month follow up survey 
Number of YWSS reporting that selling sex is the 
main way they obtain money/support themselves  
Experience of violence 
Experience of violence from partners Proportion of YWSS reporting having had a partner who hit, 
slapped, kicked, pushed, shoved or otherwise physically hurt 
her in the previous 12 months 
All YWSS participating in the 24-
month follow up survey 
Number of YWSS responding that they have been hit, 
kicked, slapped, shoved by a partner at least once in 
past 12 months 
Experience of violence from police Proportion of YWSS reporting that a member of the police hit, 
slapped, kicked, pushed, shoved or otherwise physically hurt 
her in the previous 12 months 
All YWSS participating in the 24-
month follow up survey 
Number of YWSS responding that they have been hit, 
kicked, slapped, shoved by a member of police at 
least once in past 12 months 
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analyses reflecting this design. In this study the primary aim is to estimate the impact of the DREAMS 
interventions, by making fair comparisons across the six clusters, and so we will not weight the data 
to account for recruitment using RDS - on the basis that the approach to sampling was the 
same/standardised in each cluster. However, we plan a sensitivity analysis in which weighting will be 
applied; this approach adds an additional layer of complexity, but aims to provide estimates of 
rates/prevalences for the total study population. 
Adjustment for confounding strategy: In the absence of randomisation, and also because the number 
of study clusters is low, it is appropriate to adjust the analysis for potential confounding variables. If 
we find evidence for a difference in HIV incidence between the two study arms, caution is needed 
when considering whether this difference is attributable/partly attributable to DREAMS. We 
investigated a priori what confounding factors to adjust for in order to obtain the fairest 
comparisons among study clusters. To do this, we used HIV prevalence at baseline as a “proxy” for 
the background level of HIV incidence. 
We found that HIV prevalence was different between the two study arms at baseline. We then 
identified a set of variables that we a priori thought might be associated with HIV prevalence as 
explored elsewhere,2 including age at enrolment, highest level of education attained, marital status, 
self-identification as a sex worker, STI symptoms and number of sexual partners in the past month. 
We included each variable in a univariable logistic regression model to confirm that they were 
associated with HIV prevalence and then modelled HIV prevalence against DREAMS arm adjusting 
for all six variables. Adjusting for these variables attenuated the difference in HIV prevalence 
between the two arms substantially (see Table 2). 







# of YWSS tested HIV 




































Age at enrolment 
   
<0.001 
  
   18-19 814 (36.4) 93 (11.2) 1 
   
   20-24 1555 (63.6) 450 (28.9) 3.20 (2.41-4.26) 
   
Highest level of education 
   
<0.001 
  
   Primary or less 388 (17.0) 135 (34.0) 1 
   
   Incomplete secondary 1050 (44.2) 268 (24.8) 0.64 (0.47-0.86) 
   
   Complete secondary or higher 931 (38.8) 140 (14.7) 0.33 (0.24-0.46) 
   
Marital status 
   
<0.001 
  
   Single/ never married 1385 (60.0) 242 (17.6) 1 
   
   Married/ cohabiting 48 (2.4) 12 (27.2) 1.75 (0.81-3.81) 
   
   Previously married 936 (37.6) 289 (29.9) 2.01 (1.59-2.53) 
   
Self-identification as a sex 
worker 
   
<0.001 
  
   No 724 (33.1) 113 (15.3) 1 
   
   Yes 1627 (66.9) 429 (26.2) 1.96 (1.50-2.57) 
   
STI symptoms 
   
<0.001 
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   No 1750 (74.0) 308 (16.9) 1 
   
   Yes 619 (26.0) 235 (38.2) 3.04 (2.39-3.88) 
   
Number of sexual partners in 
the past month 
   
<0.001 
  
   ≤1 213 (10.1) 37 (17.8) 1 
   
   2-5 1047 (46.1) 168 (15.7) 0.86 (0.54-1.35) 
   
   6-9 301 (12.3) 66 (20.2) 1.17 (0.70-1.97) 
   
   ≥10 808 (31.5) 272 (34.7) 2.46 (1.57-3.86) 
   
‡Adjusted for DREAMS, age at enrolment, highest level of education attained, marital status, self-identification as FSW, STI symptoms, 
number of sexual partners in the past month 
We will therefore adjust our primary analysis for these six variables, measured at baseline among 
the cohort, so as to make fairer comparisons between the two DREAMs and four non-DREAMs study 
clusters, and a fairer attribution of any difference we see to DREAMS intervention. The number of 
sero-conversions over the two-year study period may be small relative to the number of parameters 
if all six variables are included in a model. We will, therefore, need to consider the “rule-of-thumb” 
that the number of sero-conversions should be approximately ten-times higher than the number of 
parameters included in our model. If the number of sero-conversions is smaller than the number of 
parameters if all six variables are included, we will prioritise adjusting for the variables that were the 
strongest confounders of the association between prevalent HIV and DREAMS, including age and 
educational attainment if there is evidence that the model becomes unstable with the addition of 
more parameters. 
We will not be able to formally adjust our analysis for cluster level factors that may differ between 
the DREAMS and non-DREAMS districts, for example background HIV prevalence, because we have 
“only” included six clusters in the study. This is a limitation of our study described in further detail 
below 
At baseline, we also analysed how HIV prevalence increased with age among the YWSS recruited in 
DREAMS and non-DREAMS districts (see Figure 2). We fitted a simple linear regression line to HIV 
prevalence by age. We noted that, while there was a difference in the HIV prevalence at each age, as 
described above, the rate of increase of HIV prevalence with age was almost identical at 
approximately an average of 6% per single year of age increase in both groups. Among young 
women, HIV prevalence increasing with age can be cautiously interpreted as reflecting the 
underlying HIV incidence. 
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Figure 2: HIV prevalence by age and arm (blue = DREAMS sites and orange = Non-DREAMS sites)  
The combination of our data suggesting an 
i) HIV prevalence that differed between the arms at baseline, but that could be largely 
adjusted away through the addition of six key covariates measured at baseline, and 
which we will adjust our primary outcome analyses for, 
and 
ii) our finding that at baseline HIV prevalence increasing by age was near identical between 
the groups, 
provide strength to the argument we will make post-analysis, that an adjusted difference in 
measured HIV incidence between the arms can be plausibly interpreted as reflecting the effect of 
the DREAMs intervention. The further the adjusted rate ratio is from 0.8, the more credible it is that 
DREAMS had an effect on HIV incidence. Our findings will be interpreted in the context of DREAMS 
uptake. We will explore uptake of DREAMS interventions across the two study sites (as described in 
section iv); where there is evidence of differential uptake across the two groups, this would add 
credibility to any finding that the DREAMS intervention had an effect on HIV incidence. 
Reporting: Analyses will be reported in line with the Transparent Reporting of Evaluations with 
Nonrandomized Designs (TREND) statement. 
STAGES OF ANALYSIS 
i. COHORT RECRUITMENT AND RETENTION 
We will first describe recruitment into the cohort study, and present a flow chart showing the 
number of women recruited through the RDS in each district and by study arm (DREAMS and non-
DREAMS), and retention at 24-month follow-up. 
We will generate RDS recruitment trees by site, colour coding women by whether they tested HIV 
negative, HIV positive at enrolment, or tested HIV negative at enrolment and seroconverted at 24-
month follow up. We have already done the detailed RDS diagnostics which found no evidence of 
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bias with respect to HIV prevalence in either DREAMS or non-DREAMS sites and reported them 
elsewhere.2 
Using data collected on efforts to contact the women at the 24-month follow up, we will describe 
the reported reasons why women were lost to follow, for example they reportedly migrated and/or 
married, or were contacted but refused to participate. 
ii. PARTICIPANT CHARACTERISTICS AT ENROLMENT 
We will describe, by site and study arm, key demographic and behavioural characteristics of the 
women recruited to the cohort, including those that were identified to be associated with HIV 
prevalence at enrolment. We will repeat this analysis for YWSS who tested HIV negative at 
enrolment. 
iii. UPTAKE OF SERVICES 
The services delivered by DREAMS implementing partners may also be available to the women in 
non-DREAMS sites, particularly HIV testing service but also educational subsidies, and vocational 
skills training. Using 24-month follow-up data, we will describe the uptake of other services that may 
be available in and accessible to women in non-DREAMS sites, by arm and by site. 
iv. PARICIPANT CHARACTERISTICS AT 24-MONTH FOLLOW UP 
We will describe the proportion of women retained in the study at the 24-month follow-up, and 
describe follow-up by enrolment characteristics, including: age, marital status, highest level of 
education attainment and whether women self-identified as a female sex worker. 
We will repeat the descriptive analysis presented for enrolment for YWSS testing HIV negative at 
enrolment and followed up at 24 months. 
v. HIV INCIDENCE RATE BY DISTRICT AND STUDY ARM 
We will describe the number of new infections observed over the 24-month study period, and 
describe person-years of follow-up by district and study arm (Table 10). Subsequently, we will 
estimate the HIV incidence rate among the YWSS by district and by study arm. 
vi. UNADJUSTED ANALYSIS 
We will use Poisson regression to compare the HIV incidence rates across the two study arms. 
 
We will fit three models, namely: 
 
1) An unadjusted Poisson regression model 
 
vii. ADJUSTED ANALYSIS 
We will use Poisson regression models to compare the HIV incidence rates across the two study 
arms, adjusting for covariates. The models we will fit will be: 
2) An age-adjusted Poisson regression model 
3) A fully adjusted model including age and individual level potential confounders 
measured at baseline and found to be associated with HIV prevalence. 
 
viii. PRE-PLANNED SUB-GROUP ANALYSES 
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We will conduct exploratory analysis, stratifying the analysis by age and by self-identification as a sex 
worker, to get a sense of difference in the effect size among these subgroups, and will report the 
findings of these analyses. We however recognise that these analyses will likely be underpowered 
and should be interpreted cautiously. 
ix. SENSITIVITY ANALYSIS 
We will perform 2 sets of sensitivity analyses: 
1) Our primary analysis strategy does not weight the data. We will exclude seed participants 
and weight data by the inverse of women’s reported YWSS-network size and normalise 
these weights by site. 
 
2) Our primary analysis excludes data collected from women followed up at 12-months post-
enrolment in the DREAMS districts. In our second sensitivity analysis, we will add data from 
the 12-month survey in the DREAMS districts to obtain information on women not followed 
up at 24 months. In these DREAMS districts, if someone seroconverted by the time of the 
12-month follow-up, we will place the seroconversion date at the mid-point of enrolment 
and 12 months, and if someone tested HIV-negative at 12 months but HIV-positive at 24 
months, we will place the seroconversion at the mid-point 12 months and 24 months. We 
will then use this information to compare HIV incidence between the two arms. 
STRENGTHS AND LIMITATIONS 
Our primary analysis is relatively simple, providing descriptions of HIV incidence in each site and 
unadjusted and adjusted statistical comparisons between the DREAMS and non-DREAMS study 
arms. 
Our adjustment strategy includes a step-wise adjustment process, with few a priori variables 
adjusted for if they were associated with HIV prevalence at enrolment. We therefore consider the 
analysis to be transparent, and to build an evidence base for whether it is plausible that DREAMS 
had an impact on HIV incidence. 
A limitation of our analysis is that we may not have collected data on important covariates that are 
associated with HIV and important risk factors for the outcome (HIV incidence), and that differ 
among study clusters / by arm. As such, if we find evidence for an effect of DREAMS on HIV 
incidence after adjustment, we cannot be entirely sure that this effect is attributable to DREAMS. 
We are unable to conduct cluster level analysis or adjust for cluster level covariates, despite the fact 
that the intervention was allocated at cluster level. This means we will be unable to adjust for 
important potential confounders at cluster level; for example, the background HIV prevalence in the 
DREAMS clusters may differ from that in the non-DREAMS clusters owing to both the lack of 
randomisation and because of chance variability. Our interpretation will thus need to be cautious, 
commenting on any differences in cluster level factors that are observed at baseline. 
 
Our intention to treat approach will compare women eligible to receive DREAMS interventions in 
districts where DREAMS was operating with women in districts where it was not. If DREAMS delivery 
was weak, or did not reach the specific target populations of women who are the focus for our 
impact evaluation (YWSS), then we may conclude that DREAMS did not have an impact but this may 
reflect limited delivery rather than the maximum potential effect. We will describe the delivery and 
uptake of DREAMS interventions in order to support our interpretation. 
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APPENDIX 2: ADDITIONAL DESCRIPTIVE STATISTICS 
Supplemental Table 1. Key demographic and behavioural characteristics of all YWSS at enrolment 








n/N (%) n/N (%)  
HIV prevalence 234/1197 (19.5) 320/1216 (26.3) <0.001 
Age at recruitment   0.518 
  18-19 405/1204 (33.6) 428/1227 (34.9)  
  20-24 799/1204 (66.4) 799/1227 (65.1)  
Highest level of education   <0.001 
  None/ incomplete primary 41/1204 (3.4) 133/1227 (10.8)  
  Complete primary 84/1204 (7.0) 138/1227 (11.3)  
  Incomplete secondary 1018/1204 (84.5) 936/1227 (76.3)  
  Complete secondary or higher 61/1204 (5.1) 20/1227 (1.6)  
Marital status   <0.001 
  Single/ never married 801/1204 (66.5) 625/1227 (50.9)  
  Married / living together as if married 31/1204 (2.6) 19/1227 (1.6)  
  Divorced/ separated 365/1204 (30.3) 567/1227 (46.2)  
  Widowed 7/1204 (0.6) 16/1227 (1.3)  
Years selling sex   0.026 
  0-2 614/1203 (51.0) 680/1224 (55.6)  
  3+ 589/1203 (49.0) 544/1224 (44.4)  
Self-identification as sex worker   0.031 
  No  390/1191 (32.7) 350/1220 (28.7)  
  Yes  801/1191 (67.3) 870/1220 (71.3)  
Condom use at last with regular partner   0.004 
  No 320/907 (35.3) 384/919 (41.8)  
  Yes 587/907 (64.7) 535/919 (58.2)  
Condom-less sex with regular partner in the past 
month 
  0.479 
  No  498/908 (54.8) 491/923 (53.2)  
  Yes 410/908 (45.2) 432/923 (46.8)  
Condom use at last with client   0.302 
  No 105/946 (11.1) 89/923 (9.6)  
  Yes 841/946 (88.9) 834/923 (90.4)  
Condom-less sex with client in the past month   0.001 
  No  786/949 (82.8) 815/924 (88.2)  
  Yes 163/949 (17.2) 109/924 (11.8)  
STI symptoms in the last 12 months   0.003 
  No  919/1204 (76.3) 871/1227 (71.0)  
  Yes 285/1204 (23.7) 356/1227 (29.0)  
Risk of common mental disorder   <0.001 
  No 733/1204 (60.9) 840/1227 (68.5)  
  Yes 471/1204 (39.1) 387/1227 (31.5)  
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Supplemental Table 2. Key demographic and behavioural characteristics of all YWSS at enrolment by study site, 2017 
 
DREAMS Site A 
(N=601) 
DREAMS Site B 
(N=603) 
Non-DREAMS Site C 
(N=318) 
Non-DREAMS Site D 
(N=300) 
Non-DREAMS Site E 
(N=308) 
Non-DREAMS Site F 
(N=301) 
 n/N (%) n/N (%) n/N (%) n/N (%) n/N (%) n/N (%) 
HIV prevalence 128/597 (21.4) 106/600 (17.7) 84/316 (26.6) 90/299 (30.1) 42/300 (14.0) 104/301 (34.6) 
Age at recruitment       
  18-19 222/601 (36.9) 183/603 (30.3) 103/318 (32.4) 101/300 (33.7) 142/308 (46.1) 82/301 (27.2) 
  20-24 379/601 (63.1) 420/603 (69.7) 215/318 (67.6) 199/300 (66.3) 166/308 (53.9) 219/301 (72.8) 
Highest level of education       
  None/ incomplete primary 12/601 (2.0) 29/603 (4.8) 56/318 (17.6) 34/300 (11.3) 13/308 (4.2) 30/301 (10.0) 
  Complete primary 49/601 (8.2) 35/603 (5.8) 40/318 (12.6) 37/300 (12.3) 21/308 (6.8) 40/301 (13.3) 
  Incomplete secondary 512/601 (85.2) 506/603 (83.9) 219/318 (68.9) 227/300 (75.7) 271/308 (88.0) 219/301 (72.8) 
  Complete secondary or higher 28/601 (4.7) 33/603 (5.5) 3/318 (0.9) 2/300 (0.7) 3/308 (1.0) 12/301 (4.0) 
Marital status       
  Single/ never married 501/601 (83.4) 300/603 (49.8) 135/318 (42.5) 130/300 (43.3) 197/308 (64.0) 163/301 (54.2) 
  Married / living together as if married 22/601 (3.7) 9/603 (1.5) 2/318 (0.6) 3/300 (1.0) 12/308 (3.9) 2/301 (0.7) 
  Divorced/ separated 75/601 (12.5) 290/603 (48.1) 172/318 (54.1) 164/300 (54.7) 99/308 (32.1) 132/301 (43.9) 
  Widowed 3/601 (0.5) 4/603 (0.7) 9/318 (2.8) 3/300 (1.0) 0/308 (0.0) 4/301 (1.3) 
Years selling sex       
  0-2 291/600 (48.5) 323/603 (53.6) 180/318 (56.6) 173/298 (58.1) 167/307 (54.4) 160/301 (53.2) 
  3+ 309/600 (51.5) 280/603 (46.4) 138/318 (43.4) 125/298 (41.9) 140/307 (45.6) 141/301 (46.8) 
Self-identification as sex worker       
  No  223/590 (37.8) 167/601 (27.8) 65/313 (20.8) 69/300 (23.0) 151/306 (49.3) 65/301 (21.6) 
  Yes  367/590 (62.2) 434/601 (72.2) 248/313 (79.2) 231/300 (77.0) 155/306 (50.7) 236/301 (78.4) 
Condom use at last with regular partner       
  No 201/476 (42.2) 119/431 (27.6) 84/227 (37.0) 93/235 (39.6) 127/278 (45.7) 80/179 (44.7) 
  Yes 275/476 (57.8) 312/431 (72.4) 143/227 (63.0) 142/235 (60.4) 151/278 (54.3) 99/179 (55.3) 
Condom-less sex with regular partner in the past 
month       
  No  231/477 (48.4) 267/431 (61.9) 126/228 (55.3) 116/238 (48.7) 144/278 (51.8) 105/179 (58.7) 
  Yes 246/477 (51.6) 164/431 (38.1) 102/228 (44.7) 122/238 (51.3) 134/278 (48.2) 74/179 (41.3) 
Condom use at last with client       
  No 71/490 (14.5) 34/456 (7.5) 16/255 (6.3) 19/234 (8.1) 30/191 (15.7) 24/243 (9.9) 
  Yes 419/490 (85.5) 422/456 (92.5) 239/255 (93.7) 215/234 (91.9) 161/191 (84.3) 219/243 (90.1) 
Condom-less sex with client in the past month       
  No  393/491 (80.0) 393/458 (85.8) 236/255 (92.5) 216/234 (92.3) 151/192 (78.6) 212/243 (87.2) 
  Yes 98/491 (20.0) 65/458 (14.2) 19/255 (7.5) 18/234 (7.7) 41/192 (21.4) 31/243 (12.8) 
STI symptoms in the last 12 months       
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  No  470/601 (78.2) 449/603 (74.5) 235/318 (73.9) 185/300 (61.7) 248/308 (80.5) 203/301 (67.4) 
  Yes 131/601 (21.8) 154/603 (25.5) 83/318 (26.1) 115/300 (38.3) 60/308 (19.5) 98/301 (32.6) 
Risk of common mental disorder       
  No 366/601 (60.9) 367/603 (60.9) 205/318 (64.5) 189/300 (63.0) 218/308 (70.8) 228/301 (75.7) 
  Yes 235/601 (39.1) 236/603 (39.1) 113/318 (35.5) 111/300 (37.0) 90/308 (29.2) 73/301 (24.3) 
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Supplemental Table 3. Key demographic and behavioural characteristics at enrolment of YWSS 








 n/N (%) n/N (%) 
Age at enrolment 
 
 0.948 
  18-19 208/538 (38.7) 185/481 (38.5)  
  20-24 330/538 (61.3) 296/481 (61.5)  
Highest level of education 
 
 <0.001 
  None/ incomplete primary 11/538 (2.0) 24/480 (5.0)  
  Complete primary 27/538 (5.0) 61/480 (12.7)  
  Incomplete secondary 449/538 (83.5) 380/480 (79.2)  




  Single/ never married 308/538 (57.2) 182/480 (37.9)  
  Married / living together as if married 78/538 (14.5) 58/480 (12.1)  
  Divorced/ separated 152/538 (28.3) 234/480 (48.8)  
  Widowed 0/538 (0.0) 6/480 (1.3)  
Years selling sex 
 
 <0.001 
  0-2 67/537 (12.5) 99/468 (21.2)  
  3+ 470/537 (87.5) 369/468 (78.8)  
Self-identification as sex worker 
 
 0.005 
  No  217/536 (40.5) 154/480 (32.1)  
  Yes  319/536 (59.5) 326/480 (67.9)  
Condom use at last with regular partner   0.009 
  No 170/421 (40.4) 182/367 (49.6)  
  Yes 251/421 (59.6) 185/367 (50.4)  
Condom-less sex with regular partner in the past 
month 
  0.004 
  No  173/445 (38.9) 124/418 (29.7)  
  Yes 272/445 (61.1) 294/418 (70.3)  
Condom use at last with client   0.153 
  No 38/394 (9.6) 44/339 (13.0)  
  Yes 356/394 (90.4) 295/339 (87.0)  
Condom-less sex with client in the past month   0.029 
  No  321/398 (80.7) 262/354 (74.0)  
  Yes 77/398 (19.3) 92/354 (26.0)  
STI symptoms in the last 12 months   0.015 
  No  464/538 (86.2) 386/479 (80.6)  
  Yes 74/538 (13.8) 93/479 (19.4)  
Risk of common mental disorder   0.450 
  No 388/538 (72.1) 357/481 (74.2)  
  Yes 150/538 (27.9) 124/481 (25.8)  
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APPENDIX 3: PATTERNS OF RETENTION AT 24-MONTH FOLLOW-UP 
Supplemental Table 4. Age, marital status, whether women self-identified as a female sex worker and educational attainment at enrolment among 
women testing HIV negative at enrolment and retained or not retained at 24-month follow-up in 2019 
 DREAMS cities (N=963) Non-DREAMS towns (N=896) 
Follow-up rate 538/963 (55.9%) 481/896 (53.7%) 
 YWSS retained 
(N=538) 




YWSS not retained 
(N=415) P-value‡ 
 n/N (%) n/N (%) n/N (%) n/N (%) 
Age at enrolment   0.397   0.046 
  18-19 208/538 (38.7) 153/425 (36.0)  185/481 (38.5) 187/415 (45.1)  
  20-24 330/538 (61.3) 272/425 (64.0)  296/481 (61.5) 228/415 (54.9)  
Marital status   0.221   0.302 
  Single/never married 361/538 (67.1) 307/425 (72.2)  256/481 (53.2) 241/415 (58.1)  
  Married/cohabiting 12/538 (2.2) 9/425 (2.1)  8/481 (1.7) 8/415 (1.9)  
  Previously married 165/538 (30.7) 109/425 (25.6)  217/481 (45.1) 166/415 (40.0)  
Whether self-identifies as FSW   0.119   0.582 
  No 167/532 (31.4) 152/420 (36.2)  159/480 (33.1) 143/410 (34.9)  
  Yes 365/532 (68.6) 268/420 (63.8)  321/480 (66.9) 267/410 (65.1)  
Educational attainment   0.927   0.163 
  None/ incomplete primary 15/538 (2.8) 13/425 (3.1)  34/481 (7.1) 43/415 (10.4)  
  Complete primary 32/538 (5.9) 29/425 (6.8)  53/481 (11.0) 39/415 (9.4)  
  Incomplete secondary 460/538 (85.5) 357/425 (84.0)  386/481 (80.2) 321/415 (77.3)  
  Complete secondary or higher 31/538 (5.8) 26/425 (6.1)  8/481 (1.7) 12/415 (2.9)  
‡Chi-square P value for the association of each characteristic with retention at 24-month follow-up 
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APPENDIX 4: COMPARISON OF DREAMS SECONDARY OUTCOMES BY SITE 
Supplemental Table 5. Comparison of DREAMS secondary outcomes by site 
 DREAMS Site A 
(N=252) 
DREAMS Site B  
(N=286) 
Non-DREAMS Site C 
(N=122) 
Non-DREAMS Site D 
(N=102) 
Non-DREAMS Site E 
(N=141) 
Non-DREAMS Site F 
(N=115) 
 n/N (%) n/N (%) n/N (%) n/N (%) n/N (%) n/N (%) 
Improved access to clinical services and HIV prevention services 
Knowledge of HIV status       
No 71/252 (28.2) 48/286 (16.8) 27/122 (22.1) 19/102 (18.6) 37/141 (26.3) 34/115 (29.6) 
Yes 181/252 (71.8) 238/286 (83.2) 95/122 (77.9) 83/102 (81.4) 104/141 (73.7) 81/115 (70.4) 
Unadjusted 1 1.94 (1.28-2.94), p=0.002 1.38 (0.83-2.29), p=0.214 1.71 (0.97-3.03), p=0.064 1.07 (0.68-1.70), p=0.763 0.93 (0.58-1.52), p=0.785 
Fully-adjusted‡ 1 1.77 (1.14-2.74), p=0.012 1.25 (0.72-2.15), p=0.432 1.50 (0.82-2.76), p=0.186 1.03 (0.64-1.68), p=0.893 0.83 (0.50-1.38), p=0.473 
Ever taken PrEP 
   
   
No 200/252 (79.4) 187/286 (65.4) 121/122 (99.2) 102/102 (100.0) 141/142 (99.3) 114/115 (99.1) 
Yes 52/252 (20.6) 99/286 (34.6) 1/122 (0.8) 0/102 (0.0) 1/142 (0.7) 1/115 (0.9) 
Unadjusted 1 2.04 (1.38-3.01), p<0.001 – – – – 
Fully-adjusted‡ 1 1.83 (1.16-2.91), p=0.010 – – – – 
Ability to negotiate condom use 
with any partner 
      
No 26/252 (10.3) 14/286 (4.9) 5/122 (4.1) 6/102 (5.9) 55/141 (39.0) 25/115 (21.7) 
Yes 226/252 (89.7) 272/286 (95.1) 117/122 (95.9) 96/102 (94.1) 86/141 (61.0) 90/115 (78.3) 
Unadjusted 1 2.24 (1.14-4.38), p=0.019 2.69 (1.01-7.19), p=0.048 1.84 (0.73-4.62), p=0.193 0.18 (0.11-0.31), p<0.001 0.41 (0.23-0.76), p=0.004 
Fully-adjusted‡ 1 2.06 (1.02-4.18), p=0.044 2.19 (0.79-6.04), p=0.132 1.47 (0.57-3.83), p=0.428 0.16 (0.09-0.28), p<0.001 0.39 (0.21-0.73), p=0.003 
Knowledge of the HIV status 
of at least one of their three 
most recent partners 
   
   
No 68/250 (27.2) 111/278 (39.9) 45/121 (37.2) 32/100 (32.0) 65/139 (46.8) 68/114 (59.6) 
Yes 182/250 (72.8) 167/278 (60.1) 76/121 (62.8) 68/100 (68.0) 74/139 (53.2) 46/114 (40.4) 
Unadjusted 1 0.56 (0.39-0.81), p=0.002 0.63 (0.40-1.01), p=0.051 0.79 (0.48-1.31), p=0.370 0.43 (0.28-0.66), p<0.001 0.25 (0.16-0.40), p<0.001 
Fully-adjusted‡ 1 0.64 (0.43-0.96), p=0.030 0.85 (0.52-1.41), p=0.541 1.02 (0.59-1.74), p=0.953 0.44 (0.28-0.70), p<0.001 0.32 (0.19-0.52), p<0.001 
Condom-less sex with regular 
partner in the past month 
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No 122/251 (48.6) 153/285 (53.7) 58/122 (47.5) 41/100 (41.0) 52/141 (36.9) 48/115 (41.7) 
Yes 129/251 (51.4) 132/285 (46.3) 64/122 (52.5) 59/100 (59.0) 89/141 (63.1) 67/115 (58.3) 
Unadjusted 1 0.82 (0.58-1.15), p=0.241 1.04 (0.68-1.61), p=0.847 1.36 (0.85-2.18), p=0.198 1.62 (1.06-2.47), p=0.025 1.32 (0.85-2.06), p=0.222 
Fully-adjusted‡ 1 1.12 (0.73-1.71), p=0.606 1.37 (0.79-2.39), p=0.263 1.31 (0.74-2.31), p=0.358 1.58 (0.98-2.55), p=0.059 1.58 (0.89-2.81), p=0.119 
Condom-less sex with client in 
the past month 
   
   
No 214/250 (85.6) 261/285 (91.6) 109/122 (89.3) 92/100 (92.0) 106/141 (75.2) 89/115 (77.4) 
Yes 36/250 (14.4) 24/285 (8.4) 13/122 (10.7) 8/100 (8.0) 35/141 (24.8) 26/115 (22.6) 
Unadjusted 1 0.55 (0.32-0.94), p=0.031 0.71 (0.36-1.39), p=0.318 0.52 (0.23-1.16), p=0.108 1.96 (1.17-3.30), p=0.011 1.74 (0.99-3.05), p=0.054 
Fully-adjusted‡ 1 0.61 (0.32-1.18), p=0.144 0.60 (0.26-1.42), p=0.247 0.62 (0.25-1.57), p=0.317 2.30 (1.21-4.37), p=0.011 1.98 (1.01-3.86), p=0.045 
Accessed STI treatment services 
in the past 12 months 
      
No 2/32 (6.3) 5/42 (11.9) 3/20 (15.0) 2/32 (6.3) 8/21 (38.1) 5/20 (25.0) 
Yes 30/32 (93.8) 37/42 (88.1) 17/20 (85.0) 30/32 (93.8) 13/21 (61.9) 15/20 (75.0) 
Unadjusted 1 0.49 (0.09-2.72), p=0.418 0.38 (0.06-2.49), p=0.312 – 0.11 (0.02-0.58), p=0.010 0.20 (0.03-1.15), p=0.072 
Fully-adjusted‡ 1 – 0.22 (0.01-12.18), p=0.463 – 0.25 (0.01-5.52), p=0.383 – 
Improved coverage of Social and Economic Protection service 
Food insecurity 
   
   
No 191/252 (75.8) 176/286 (61.5) 35/122 (28.7) 54/102 (52.9) 118/140 (84.3) 88/115 (76.5) 
Yes 61/252 (24.2) 110/286 (38.5) 87/122 (71.3) 48/102 (47.1) 22/140 (15.7) 27/115 (23.5) 
Unadjusted 1 1.96 (1.35-2.84), p<0.001 7.78 (4.78-12.66), p<0.001 2.78 (1.72-4.52), p<0.001 0.58 (0.34-1.01), p=0.050 0.96 (0.57-1.61), p=0.880 
Fully-adjusted‡ 1 1.56 (1.04-2.35), p=0.034 5.66 (3.34-9.61), p<0.001 2.52 (1.48-4.29), p=0.001 0.54 (0.31-0.95), p=0.033 0.87 (0.51-1.51), p=0.626 
Selling sex is the main way to 
support myself 
      
No 105/252 (41.7) 91/286 (31.8) 37/122 (30.3) 34/102 (33.3) 60/140 (42.9) 28/115 (24.3) 
Yes 147/252 (58.3) 195/286 (68.2) 85/122 (69.7) 68/102 (66.7) 80/140 (57.1) 87/115 (75.7) 
Unadjusted 1 1.53 (1.08-2.18), p=0.018 1.64 (1.04-2.60), p=0.035 1.43 (0.88-2.31), p=0.147 0.95 (0.63-1.45), p=0.819 2.22 (1.35-3.64), p=0.002 
Fully-adjusted‡ 1 1.32 (0.90-1.94), p=0.150 1.18 (0.72-1.94), p=0.507 1.13 (0.67-1.89), p=0.655 0.97 (0.63-1.51), p=0.906 2.09 (1.25-3.49), p=0.005 
Ever been unable to decline sex 
in the past month 
   
   
Never/not in the past month 129/252 (51.2) 128/282 (45.4) 64/119 (53.8) 53/99 (53.5) 76/141 (53.9) 43/115 (37.4) 
At least once in the past month 123/252 (48.8) 154/282 (54.6) 55/119 (46.2) 46/99 (46.5) 65/141 (46.1) 72/115 (62.6) 
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Unadjusted 1 1.26 (0.90-1.77), p=0.181 0.90 (0.58-1.40), p=0.641 0.91 (0.57-1.45), p=0.692 0.90 (0.59-1.36), p=0.606 1.76 (1.12-2.76), p=0.014 
Fully-adjusted‡ 1 1.25 (0.87-1.80), p=0.235 0.89 (0.55-1.44), p=0.633 0.89 (0.54-1.47), p=0.649 0.95 (0.62-1.45), p=0.805 1.72 (1.08-2.74), p=0.023 
Number of sex work clients in 
the past month 
      
≤3 138/252 (54.8) 145/285 (50.9) 39/116 (33.6) 38/96 (39.6) 86/141 (61.0) 40/115 (34.8) 
>3 114/252 (45.2) 140/285 (49.1) 77/116 (66.4) 58/96 (60.4) 55/141 (39.0) 75/115 (65.2) 
Unadjusted 1 1.17 (0.83-1.64), p=0.368 2.39 (1.51-3.78), p<0.001 1.85 (1.15-2.98), p=0.012 0.77 (0.51-1.18), p=0.232 0.27 (1.44-3.58), p<0.001 
Fully-adjusted‡ 1 1.12 (0.76-1.63), p=0.574 1.87 (1.13-3.10), p=0.015 1.56 (0.92-2.64), p=0.100 1.10 (0.70-1.74), p=0.671 2.28 (1.38-3.75), p=0.001 
Gender-based violence prevention, and care and support services 
Experience of violence from 
partners in the past 12 months 
   
   
No 210/252 (83.3) 224/286 (78.3) 76/122 (62.3) 73/102 (71.6) 108/142 (76.1) 88/115 (76.5) 
Yes 42/252 (16.7) 62/286 (21.7) 46/122 (37.7) 29/102 (28.4) 34/142 (23.9) 27/115 (23.5) 
Unadjusted 1 1.38 (0.90-2.14), p=0.143 3.03 (1.85-4.96), p<0.001 1.99 (1.15-3.42), p=0.013 1.57 (0.95-2.62), p=0.080 1.53 (0.89-2.64), p=0.123 
Fully-adjusted‡ 1 1.14 (0.71-1.83), p=0.583 2.30 (1.34-3.96), p=0.003 1.39 (0.77-2.49), p=0.275 1.56 (0.91-2.66), p=0.104 1.56 (0.88-2.76), p=0.129 
Experience of violence from 
police in the past 12 months 
   
   
No 249/252 (98.8) 282/286 (98.6) 122/122 (100.0) 102/102 (100.0) 137/140 (97.9) 112/115 (97.4) 
Yes 3/252 (1.2) 4/286 (1.4) 0/122 (0.0) 0/102 (0.0) 3/140 (2.1) 3/115 (2.6) 
Unadjusted 1 1.18 (0.26-5.31), p=0.832 – – 1.82 (0.36-9.13), p=0.468 2.22 (0.44-11.19), p=0.332 
Fully-adjusted‡ 1 0.87 (0.17-4.44), p=0.869 – – 1.81 (0.33-9.74), p=0.492 1.62 (0.29-8.95), p=0.581 
‡Adjusted for age, highest level of education attained, marital status, self-identification as FSW (measured at baseline), and for each respective secondary outcome measured at baseline 
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APPENDIX 5: RDS DIAGNOSTICS AND RESULTS 
RDS diagnostics were based on enrolment (2017) data. Combined convergence and bottleneck plots 
(reported elsewhere),2 suggested that key characteristics and outcomes, including age, whether 
women self-identified as FSW and HIV prevalence, stabilised with increasing sample sizes in five of 
the six sites. There was also little evidence of disconnected networks of YWSS in each site. In this 
study, we report the proportion of women who said that they were recruited into the study by 
strangers, to have an understanding of reciprocity, and assessed recruitment homophily with respect 
to HIV status, to understand if HIV positive recruiters preferentially recruited HIV positive peers from 
amongst their personal networks. 
We generated RDS recruitment trees by site, colour coding women by whether they tested HIV 
negative at enrolment, HIV positive at enrolment, or tested HIV negative at enrolment and 
seroconverted at 24-month follow up. Detailed RDS diagnostics for these data are presented 
elsewhere.2 
Supplemental Table 6. Proportion recruited by strangers, and recruitment homophily for HIV 
status 
Site Proportion recruited by strangers Homophily for HIV status 
DREAMS Site A 7.1 1.0 
DREAMS Site B 21.1 1.0 
Non-DREAMS Site C 5.7 1.0 
Non-DREAMS Site D 20.6 0.9 
Non-DREAMS Site E 21.8 1.0 
Non-DREAMS Site F 27.8 1.0 
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Supplemental Figure 1. Recruitment trees. Red circles represent women who tested HIV positive at enrolment, green circles represent women who 
tested HIV negative at enrolment, and blue circles represent women who tested HIV negative at enrolment who seroconverted at 24-month follow-up. 
The larger circles denote speed participants. 
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Supplemental Table 7. Follow-up interview questions to assess whether respondent-driven sampling strategy worked well in 2017 
 
DREAMS Site A‡ 
(N=137) 
n/N (%) 
DREAMS Site B 
(N=270) 
n/N (%) 
Non-DREAMS Site C 
(N=120) 
n/N (%) 
Non-DREAMS Site D 
(N=96) 
n/N (%) 
Non-DREAMS Site E 
(N=153) 
n/N (%) 
Non-DREAMS Site F 
(N=120) 
n/N (%) 
Apart from the woman who did recruit you to the study, has 
anyone else approached you to give you a coupon? 
      
No 38/45 (84.4) 248/270 (91.9) 88/120 (73.3) 70/96 (72.9) 151/153 (98.7) 119/120 (99.2) 
Yes 7/45 (15.6) 22/270 (8.1) 32/120 (26.7) 26/96 (27.1) 2/153 (1.3) 1/120 (0.8) 
If yes, how many times has this happened? 
      
Once 1/5 (20.0) 16/22 (72.7) 11/32 (34.4) 16/24 (66.7) – – 
Twice 3/5 (60.0) 5/22 (22.7) 12/32 (37.5) 6/24 (25.0) – – 
Three or more times 1/5 (20.0) 1/22 (4.5) 9/32 (28.1) 2/24 (8.3) – – 
How many YWSS (aged over 18) do you know personally who live 
in this site, where you know their name and they know yours 
      
median (p25-p75) 6 (5-10) 5 (4-10) 10 (5-15) 6 (4-10) 6 (5-15) 6 (4-10) 
Of these YWSS whom you know personally, how many have you 
seen in the last month? 
      
median (p25-p75) 5 (4-9) 4 (3-7) 8 (5-10) 6 (4-10) 5 (3-10) 5 (4-10) 
Of the YWSS whom you know personally, how many would you 
have considered asking to take part in the study? 
      
median (p25-p75) 5 (4-8) 4 (2-7) 4 (2-7) 4 (2-7) 5 (2-10) 4 (2-7) 
How many women did you give a coupon to who accepted it? 
      
0 0/44 (0.0) 2/270 (0.7) 1/117 (0.9) 0/95 (0.0) 0/153 (0.0) 0/120 (0.0) 
1 2/44 (4.5) 5/270 (1.9) 11/117 (9.4) 7/95 (7.4) 19/153 (12.4) 12/120 (10.0) 
2 42/44 (95.5) 263/270 (97.4) 105/117 (89.7) 88/95 (92.6) 134/153 (87.6) 108/120 (90.0) 
How many women did you try to recruit to the survey but who 
refused? 
      
0 37/44 (84.1) 226/256 (88.3) 88/118 (74.6) 68/94 (72.3) 133/153 (86.9) 106/117 (90.6) 
1 2/44 (4.5) 12/256 (4.7) 16/118 (13.6) 11/94 (11.7) 14/153 (9.2) 9/117 (7.7) 
2 3/44 (6.8) 10/256 (3.9) 8/118 (6.8) 11/94 (11.7) 2/153 (1.3) 0/117 (0.0) 
≥3 2/44 (4.5) 8/256 (3.1) 6/118 (5.1) 4/94 (4.3) 4/153 (2.6) 2/117 (1.7) 
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‡Lot of missing data in site A due to errors in questionnaire skip patterns 
Across all the study sites, some women were approached more than once to participate in the study (Supplemental Table 7), and very few women refused 
the coupon they were offered. 
 
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Global Health
 doi: 10.1136/bmjgh-2020-003892:e003892. 6 2021;BMJ Global Health, et al. Chabata ST
24 
APPENDIX 6: SENSITIVITY ANALYSES 
We conducted sensitivity analyses in which we (i) included data collected from women followed up at 12-months post-enrolment in the DREAMS sites, and 
(ii) RDS-II weighted our data, where the 24-momth data was weighted using RDS weights that were generated using enrolment. For (i), we only present the 
primary outcome results which are very similar to that of the primary analysis results, and we do not present the results of uptake of DREAMS and 
secondary outcomes results because they are also very similar to that of primary analysis. 
Supplemental Table 8. HIV incidence among YWSS testing HIV negative at enrolment, by arm (A) and site (B) (N=1138) (including 12-month follow-up 
data) 
‡Adjusted for age, highest level of education attained, marital status, self-identification as FSW, STI symptoms, number of sexual partners in the past month, HIV prevalence (measured at enrolment) 




years of follow-up 
Rate per 100 
person-years (95% 
CI) 
Age-adjusted rate ratio 
(95%CI) 
p-value 
Fully adjusted rate ratio 
(95%CI)‡ 
p-value 
Non-DREAMS (N=479) 48/907.62 5.29 (3.99-7.02) 1.0 1.0 





B. Comparison of HIV incidence among YWSS testing HIV negative at enrolment, by site 
DREAMS Site A (n=309) 24/493.94 4.86 (3.26-7.25) 1.0  
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Supplemental Table 9. HIV incidence among YWSS testing HIV negative at enrolment, by group (A) and site (B) (N=1017) (RDS weighted) 
‡Adjusted for age, highest level of education attained, marital status, self-identification as FSW, STI symptoms, number of sexual partners in the past month, HIV prevalence (measured at enrolment) 
  




years of follow-up 
Rate per 100 
person-years (95% 
CI) 
Age-adjusted rate ratio 
(95%CI) 
p-value 
Fully adjusted rate ratio 
(95%CI)‡ 
p-value 
Non-DREAMS (N=479) 48/907.62 5.61 (3.77-7.46) 1.0 1.0 





B. Comparison of HIV incidence among YWSS testing HIV negative at enrolment, by site 
DREAMS Site A (n=252) 16/444.74 3.49 (1.44-5.53) 1.0  
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Supplemental Table 10. HIV incidence among young women who sell sex testing HIV negative at enrolment, by arm (A) and site (B) (N=1017) (Imputed 
seroconversion date) 




years of follow-up 
Rate per 100 
person-years (95% 
CI) 
Age-adjusted rate ratio 
(95%CI) 
p-value 
Fully adjusted rate ratio 
(95%CI)‡ 
p-value 
Non-DREAMS (N=479) 48/907.60 5.29 (3.99-7.02) 1.0 1.0 





B. Comparison of HIV incidence among YWSS testing HIV negative at enrolment, by site 
DREAMS Site A (n=252) 16/444.06 3.60 (2.21-5.88) 1.0  
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DREAMS vs non-DREAMS 
 
n/N (%) n/N (%) OR (95% CI) P-value 
Direct HIV Prevention and Clinical services 
Recently HIV tested (within 6mths prior to the survey) 
  
  
No 181/537 (36.6) 152/478 (33.8)   
Yes 356/537 (63.4) 326/478 (66.2) 1.39 (0.81-2.37) 0.234‡ 
Ever been offered PrEP     
No 285/538 (55.5) 476/481 (99.0)   
Yes 253/538 (44.5) 5/481 (1.0) – <0.001§ 
Current use of contraceptive methods (including condom) 
  
  
No 61/495 (11.8) 101/432 (27.3)   
Yes 434/495 (88.2) 331/432 (72.7) 1.79 (0.81-3.93) 0.148‡ 
Attendance to Sisters with a Voice Clinic in past 12 months 
  
  
No 221/538 (43.4) 344/480 (73.0)   
Yes 317/538 (56.6) 136/480 (27.0) 14.54 (7.36-28.75) <0.001‡ 
Saw condom promotion activities in the past 12 months     
No 175/536 (34.0) 225/479 (48.2)   
Yes 361/536 (66.0) 254/479 (51.8) 1.86 (1.10-3.16) 0.022‡ 
Attendance to Sisters with a Voice community mobilisation meeting in past 
12 months 
    
No 464/537 (86.8) 453/480 (94.3)   
Yes 73/537 (13.2) 27/480 (5.7) 17.24 (2.32-128.20) 0.005‡ 
Social and Economic Protection Services 
Receipt of cash transfer or educational subsidy in past 12 months 
  
  
No 516/538 (96.1) 480/480 (100.0)   
Yes 22/538 (3.9) 0/480 (0.0) – <0.001§ 
Participation in continuing education programme in past 12 months 
  
  
No 528/538 (98.2) 480/480 (100.0)   
Yes 10/538 (1.8) 0/480 (0.0) – 0.018§ 
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Global Health
 doi: 10.1136/bmjgh-2020-003892:e003892. 6 2021;BMJ Global Health, et al. Chabata ST
28 
Participation in job preparation training in past 12 months 
  
  
No 529/538 (98.1) 480/480 (100.0)   
Yes 9/538 (1.9) 0/480 (0.0) – 0.024§ 
Participation in apprenticeship in past 12 months¶ 
  
  
No 538/538 (100.0) 480/480 (100.0)   
Yes 0/538 (0.0) 0/480 (0.0) – – 
Participation in internal savings & loan group in past 12 months     
No 514/537 (96.1) 479/479 (100.0)   
Yes 23/537 (3.9) 0/479 (0.0) – <0.001§ 
Gender-based Violence Care and Support Services 
Accessed healthcare services after experiencing GBV in past 12 months†     
No 49/63 (77.4) 40/48 (84.9)   
Yes 14/63 (22.6) 8/48 (15.1) 1.48 (0.20-11.00) 0.701‡ 
Provided with shelter in past 12 months (among women experiencing GBV)     
No 188/189 (99.3) 181/183 (99.3)   
Yes 1/189 (0.7) 2/183 (0.7) – 0.922§ 
†Among YWSS who experienced sexual violence 
‡Age and site adjusted Wald test p-value 
§Fisher’s exact p-value – OR and 95% CI could not be estimated using logistic regression due to sparse data 
¶Fisher’s exact p-value or OR and 95% CI could not be estimated due to sparse data 
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Supplemental Table 12. Comparison of DREAMS secondary outcomes between the two DREAMS cities and the four non-DREAMS comparison towns, 
2019 (RDS weighted) 
 DREAMS cities Non-DREAMS towns DREAMS vs non-DREAMS 
 (N=538) (N=481) Age-adjusted Fully-adjusted‡ 
 n/N (%) n/N (%) OR (95% CI) P-value OR (95% CI) P-value 
Improved access to clinical services and HIV prevention services 
Knowledge of HIV status       
No 119/538 (24.8) 118/481 (25.7)     
Yes 419/538 (75.2) 363/481 (74.3) 1.07 (0.76-1.51) 0.694 1.12 (0.78-1.60) 0.533 
Ever taken PrEP       
No 387/538 (74.4) 478/481 (99.3)     
Yes 151/538 (25.6) 3/481 (0.7) 47.94 (14.61-157.38) <0.001 49.52 (14.62-167.78) <0.001 
Ability to negotiate condom use with any 
partner 
      
No 40/538 (7.9) 91/480 (20.7)     
Yes 498/538 (92.1) 389/480 (79.3) 3.11 (1.95-4.98) <0.001 3.68 (2.24-6.04) <0.001 
Knowledge of the HIV status of at 
least one of their three most recent 
partners 
      
No 179/528 (35.8) 210/474 (43.8)     
Yes 349/528 (64.2) 264/474 (56.2) 1.39 (1.03-1.87) 0.032 1.30 (0.94-1.78) 0.108 
Condom-less sex with regular partner in 
the past month 
      
No 275/536 (53.0) 199/478 (41.2)     
Yes 261/536 (47.0) 279/478 (58.8) 0.62 (0.46-0.83) 0.001 0.65 (0.45-0.93) 0.017 
Condom-less sex with client in the past 
month 
      
No 475/535 (89.8) 396/478 (83.4)     
Yes 60/535 (10.2) 82/478 (16.6) 0.57 (0.37-0.85) 0.007 0.57 (0.35-0.93) 0.024 
Accessed STI treatment services in the 
past 12 months§ 
      
No 7/74 (10.0) 18/93 (20.9)     
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Yes 67/74 (90.0) 75/93 (79.1) 2.49 (0.85-7.28) 0.096 – – 
Improved coverage of Social and Economic Protection service 
Food insecurity       
No 367/538 (70.6) 295/479 (60.7)     
Yes 171/538 (29.4) 184/479 (39.3) 0.65 (0.48-0.88) 0.005 0.66 (0.48-0.92) 0.014 
Selling sex is the main way to support 
myself 
      
No 196/538 (38.5) 159/479 (36.3)     
Yes 342/538 (61.5) 320/479 (63.7) 0.93 (0.68-1.27) 0.650 0.97 (0.70-1.34) 0.845 
Ever been unable to decline sex in the 
past month 
      
Never/not in the past month 257/534 (50.3) 236/474 (52.6)     
At least once in the past month 277/534 (49.7) 238/474 (47.4) 1.10 (0.82-1.47) 0.513 1.09 (0.80-1.48) 0.586 
Number of sex work clients in the past 
month 
      
≤3 283/537 (56.3) 203/468 (47.0)     
>3 254/537 (43.7) 265/468 (53.0) 0.69 (0.52-0.93) 0.014 0.63 (0.46-0.87) 0.005 
Gender-based violence prevention, and care and support services 
Experience of violence from partners in 
the past 12 months 
      
No 434/538 (83.0) 345/481 (72.6)     
Yes 104/538 (17.0) 136/481 (27.4) 0.55 (0.39-0.77) 0.001 0.53 (0.36-0.76) 0.001 
Experience of violence from police in the 
past 12 months 
      
No 531/538 (99.1) 473/479 (98.8)     
Yes 7/538 (0.9) 6/479 (1.2) 0.74 (0.20-2.72) 0.652 0.68 (0.18-2.54) 0.565 
‡Adjusted for age, highest level of education attained, marital status, self-identification as FSW (measured at baseline), and for each respective secondary outcome measured at enrolment 
§OR and 95% CI could not be estimated using logistic regression due to sparse data 
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